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CHAPTER I 
INTRODUCTION 
Snake venom is a complex mixture or proteins, carbo-
hydrates, nucleotides and other components which can 
cause deleterious errects such as systemic hemorrhage, 
local tissue damage and death (Tu, 1977). The most common 
treatment ror rattlesnake venom poisoning in the United 
States and parts or Central and South America is the use or 
a polyvalent antivenom known as Antivenin (Crotalidae) 
( Russe 1 1 et a l • , 1 973) • 
Treatment or the snakebite victim may involve the 
intravenous administration or ten or more units or the 
antivenin, and still there may be the loss or severe 
crippling or the hand or root (Lockhart, 1977). Thererore, 
the errectiveness or polyvalent antivenin in treating local 
myonecrosis has been questioned (Stante, 1969; Glenn and 
Straight, 1977). It has been demonstrated that antivenin 
has the ability to neutralize both hemorrhage (Ownby et 
al.~ 1984) and lethality (Ownby et al., 1983a) caused by 
Prairte rattlesnake (Crotalus viridis viridis) venom. How-
ever it has little ability to neutralize local myonecrosis 
(Ownby et al., 1983a). Antiserum to myotoxin §,a pure 
toxin isolated rrom ~- y. viridis venom (Ownby et al., 
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1976), is more effective than polyvalent antivenin in 
neutralizing the myotoxicity produced by both pure myotoxin 
~and crude C. y. viridis venom (Ownby et al., 1983a). 
These results correlate well with the very low titer of 
antibodies to myotoxin ~detected in polyvalent antivenin 
using immunodiffusion or the enzyme-1 inked immunosorbent 
assay (ELISA) (Ownby et al., 1983b). Thus, an antiserum 
containing antibodies to myotoxin 2 offers the possiblity 
for improvement in the treatment of snakebite poisoning. 
Myotoxin 2 is the major myotoxic component of ~- y. 
viridis venom (Cameron and Tu, 1917) and produces 
myonecrosis very similar to the crude venom (Stringer et 
al., 1972). It has also been detected in the venoms of 
other rattlesnakes Crotalus durissus terrificus (Cameron 
and Tu, 1978), Crotalus vir.idis concolor (Pool et al ., 
1981) and Crotalus viridis helleri (Maeda et al., 1978). 
Treatment following poisoning by these rattlesnakes and 
possibly others should take into consideration the presence 
of myotoxin 2· Currently, however, very little is known 
regarding the amount of antivenin to administer or how the 
presence and amount of venom alters the disappearance of 
the antivenom. Improvement in snakebite treatment, 
therefore, must involve assays that are able to detect and 
moniter antiserum levels. In addition, an assay that can 
detect specific toxic components in venoms could provide 
extremely useful information to the clinician for proper 
treatment of snakebite poisoning. 
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The enzyme-linked immunosorbent assay (ELISA) is a 
test that is both sensitive and rapid. The ELISA system 
has been used for antigen detection (Minton, 1977; Ho et 
al., 1986a), however its sensitivity to a large degree is 
dependent on the quality of the reagents (Ho et al., 
1986a). Ho et al. (1986a) have used a purified lgG 
fraction obtained from a protein A column to improve the 
sensitivity of their venom detection assay. A similar 
approach should also be taken for an antibody detection 
ELISA system. 
The use of an affinity purified antibody, specifical-
ly antimyotoxin, could 1) provide a sensitive assay with 
low non-specific binding, 2) permit a rapid test for the 
monitoring and quantitation of antiserum in blood samples, 
3) possibly be used for the neutralization of its specific 
antigen and 4) also be helpful in establishing an antigen 
detection ELISA system useful in the screening of venoms 
for the presence of myotoxin s· 
Therefore, in this study antibodies to myotoxin s• 
subsequently called myotoxin, were affinity purified and 
tested for their ability to neutralize local myonecrosis. 
The affinity purified antimyotoxin protein was used to set 
up an ELISA system for the detection of antibodies to 
myotoxin gin blood samples from mice, and to establish an 
ELISA for antigen detection. The antibody detection assay 
was used to detect changes in vivo in the level of anti-
myotoxin in the presence and absence of myotoxin s over a 
given period of time. In addition, a myotoxin detection 
ELISA was used in vitro to screen numerous crotalid venoms 
from various geographic regions for the presence of 
myotoxin. 
4 
CHAPTER II 
LITERATURE REVIEW 
Snakebite Management 
The incidence or snakebites in the United States has 
been estimated For the period 1950-1959 to be 45,000 bites 
per year (Parrish, 1980), or which 8000 are due to venomous 
snakes and or these 6800 are reported (Russel 1, 1969). In 
the United States alone there are about 120 species or 
snakes or which approximately 20 species have proven 
poisonous (Russel 1 et al ., 1975). The vast majority or the 
poisonous snakes in the United States are pit vipers, 
subFamily Crotalidae. Pit vipers include rattlesnakes, 
genus Crotalus; cottonmouths and copperheads, genus 
Agkistrodon; plus the massasauga and pigmy rattlesnakes, 
genus Sistrurus (Clement, 1979). Although pit viper bites 
are seldom Fatal, Fewer than twelve deaths per year 
(Minton, 1971; Glass, 1976), local tissue damage with the 
sequelae or loss or Function, deFormity and even amputation 
proves a persistent problem in snakebite treatment. 
The treatments recommended For snakebite envenomation 
are stil 1 today considerably varied and controversial. The 
lack or a standardized treatment For snakebite envenomation 
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is due partially to the ract that the errects rol lowing 
envenomation are related to the species or the snake, the 
quantity or venom injected, age and condition or the 
victim, and the length or time which has elapsed before 
seeking treatment (Klauber, 1956; Parrish and Hayes, 1970; 
Ho et al., 1986b). The time lapse before the snakebite 
victim receives professional attention can vary extensively 
especially with geographical region (Lockhart, 1965: Glenn 
et al ., 1983: Reid and Theakston, 1983). 
Snakebite management varies rrom the very aggressive 
surgical method or Huang et al. (1973) which includes 
excisional therapy along with extensive incision and 
debridement or the bite site including the subcutaneous 
tissue, to the less invasive treatment or antivenin 
administration. Prior_to 1970 the most frequent treatments 
used were cryotherapy, incision and suction, steriods, and 
polyvalent antivenin (Huang et al., 1978). 
Excisional Therapy 
Excisional therapy is the surgical removal or the 
envenomated tissue. The rational behind the use or 
excisional therapy in the case or a snakebite is the 
physical removal or venom which remains localized at the 
bite site ror a short period or time (Huang, 1974). The 
systemic errects are hop~rully also lessened since the 
blood levels or the venom are decreased by the tissue 
removal. However, this somewhat primative treatment or 
snakebite by excision of tissue at the bite -site has never 
shown significant benefit (Gennaro and McCullough, 1961). 
Huang et al. (1974) have reported treatment of 54 pit viper 
bites using excisional therapy, and although there was no 
mortality, the patients showed signs of necrosis, sloughing 
of skin grafts and deformities. Gutierrez et al. (1984) 
have shown that skeletal muscle regeneration does occur 
after myonecrosis induced by Bothrops asper venom. Removal 
of necrotic tissue may eliminate the myogenic cells 
responsible for muscle regeneration~ 
Incision and Suction 
It has also been reported that treatment of snakebite 
by incision and suction can reduce the venom dose by fifty 
percent if administered within three minutes of the 
snakebite. After longer periods of time the venom binds to 
the tissue and is no longer available for removal by this 
method (Gennaro, 1977). Therapy by incision and suction has 
never been shown to benefit human victims of viper bites, 
since usually sufficient time has elapsed that makes any 
attempt to remove the venom by this method useless (Arnold, 
1979). In fact prolonged suction may result in additional 
tissue damage (McCullough and Gennaro, 1968). Incisions 
can also aggravate bleeding, especially in bites causing 
non-clotting blood, as well as damaging nerves and tendons, 
introducing infection and delaying healing (Reid and 
Theakston, 1983). 
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Cryotherapy 
The use or cryotherapy ror snakebite victims was 
recommended twenty-rive years ago as a means to decrease 
the enzymatic activity or the-\tenom by lowering the 
temperature or the arrected limb (Arnold, 1975), and thus 
reducing local tissue damage until hospital treatment might 
become available (Gennaro and Watt, 1977). Cryotherapy is 
the practice or packing the site or envenomation in ice or 
immersing it in ice water ror hours to days in order to 
prevent tissue destruction (Lockhart, 1965; Stahnke and 
McBride, 1966). However, the use or cryotherapy ror 
treatment or snakebite envenomation has been shown to cause 
additional tissue damage (Bennett et al ., 1961; McCullough 
and Gennaro, 1970). Gennaro et al. (1977) reported the 
results or a clinical analysis or thirty-six snakebite 
victims. They round that seventy-rive percent or the 
amputations had received cryotherapy rrom a period or 
twelve hours to three weeks. Cryotherapy has also been 
investigated experimentally by Yap and Perry (1960) and 
Gill (1970). Their results indictate an increase in local 
tissue damage and a prolonged disability when cryotherapy 
is used. 
Tourniguets 
In the past it has been suggested by investigators 
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(Trinca, 1963; Stahnke, 1966) that the use of tourniquets 
could prevent the proximal spread of the venom, and thus 
keeping the venom in the extremity would reduce both 
morbidity and mortality. However, tourniquets also 
decrease normal tissue perfusion increasing ischemia and 
thereby also increasing tissue damage. It has been 
recommended that tourniquets be applied only tightly enough 
to impede the flow in superficial lymphatics and veins. 
Venom however does not spread by superficial lymphatics and 
veins (McCullough and Gennaro, 1970), and if edema pro-
gresses proximal to the tourniquet, the tourniquet will 
tighten and perfusion will be decreased (Soloman et al., 
1968). Tourniquets not only fail to delay the absorption 
of venom into the circulation (Ho et al., 1986) but as a 
consequence of too tightly applied tourniquets amputations 
have been reported (Synder et al., 1972; Hopkins, 1976). 
Corticosteroids 
The use of corticosteroids in initial therapy of 
serious pit viper envenomations has been reported, however 
the results remain controversial (Minton, 1971; Henderson 
and Dujun, 1973). Mohamed and Kamel (1963) reported that 
cortisone with atropine did reduce mortality in dogs and 
rabbits subjected to the venom from the Egyptian black 
snake (Walterinnesia aegyptea), and did not appear to 
affect the neutralizing capability of the antivenin. 
However, numerous other investigations (Schettler, 1954b; 
9 
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Clark, 1971) have shown through clinical and laboratory 
trials that cortisone offered no benefit to the snakebite 
patient. Russell (1965) demonstrated that. rabbits 
reee-hrl·ng cortisone plus venom during the venom immuniza-
tion program fared not as well as the rabbits receiving the 
venom alone. This finding supports previously reported 
studies, which showed that corticosteroids fail to protect 
laboratory animals against the LDso of the venom and in 
some cases may actually enhance the action or the venom or 
suppress the animal's immunological defense mechanisms 
(Schettler, 1954b; Russell and Emery 1961; Gennaro, 1963). 
In human subjects it has also been found that prednisone 
failed to lessen either local or systemic effects of 
. 
Maylayan pit viper bites (Reid et al., 1963). It therfore, 
seems unlikely that cortisone is of any benefit in the 
treatment of snakebite victims since it has not been shown· 
.to have any effect on the snake venom or on biologically 
active substances resulting from envenomation (Arnold, 
1976). 
Antivenin Treatment 
The snakebite treatments that have been discussed 
have obvious disadvantages often leading to complications 
which can increase morbidity and hinder recovery. Many 
investigators and physicians realize the need to improve 
snakebite treatment. Therefore, the production and use of 
antivenins for snakebite management is an area which has 
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been studied, and reports discussing its advantages and 
disadvantages can be round in the literature (Schettler, 
1954a; Loprinzi et al ., 1983; Kornal ik et al., 1983; Ownby 
et a 1 • , 1986) . Treatment a 1 one is not __ j:b_~ _ _qn 1 y Factor to 
inFluence the patient's recovery, also the toxicity and 
quantity or venom, depth and location or the bite, the 
ability or the body's deFenses to respond and the time 
lapse between injury and treatment (Minton,· 1954). The 
eFFicacy or an antivenin to neutralize the toxicity or the 
snake venom is due in large part to the length or time that 
has elasped prior to treatment as well as the antibody 
titer to a particular snake venom component (Ownby et al., 
1983a). 
Polyvalent antivenoms. There is the need For potent, 
safe polyvalent antivenoms in regions where more than one 
species of snakes exist (Mohamed et al., 1977). A single 
venom has been reported to produce a more eFFective 
species-speciFic (monovalent) antivenom than an antiserum 
composed oF antibodies against one or more other venoms 
(polyvalent) antivenom (Russel 1 and Lauritzen, 1966). How-
ever it is normally impractical to produce a large number 
or monovalent species-speciFic antisera, especially when 
the snakebite victim is often uncertain about the type oF 
snake which inFlicted the bite. Monovalent and polyvalent 
antivenoms are produced commerical ly by twenty-eight 
laboratories in twenty countries (Minton, 1967). In the 
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United States, Europe, Asia,_ and other regions.of' the world 
polyv~lent antivenoms are commerically available (Taub, 
1964; Stanic, 1969; Ganthavorn, 1969). However, the 
ef'f'icacy of' the antivenom against hemorrhagic, lethal and 
myotoxic components of' the snake venom are variable (Ownby 
et al ., 1983a). The results of' Ownby et al. (1983a) 
indicated that unless the polyvalent (Crotalidae) antivenin 
is given immediately af'ter the venom From the Prairie 
rattlesnake (~. viridis viridis), it is not eFFective in 
neutralizing local myonecrosis. The polyvalent antivenom 
was quite eFFective, however, in neutralizing the lethal 
eFFects of' the venom (Ownby et al., 1983a). It has also 
been shown by immunodiFFusion and enzyme-1 inked 
immunosorbent assay (ELISA) (Ownby et al., 1983b) that the 
antibody titer of' anti-myotoxin in the commerically 
produced polyvalent antivenin is very low, thus providing a 
logical reason f'or the polyvalent antivenin's poor 
neutralizing capability against local myonecrosis. Russell 
et al. (1973) observed moderate local tissue damage in rats 
receiving antivenin ten minutes Following a venom 
injection, if' twenty minutes elapsed prior to treatment 
with antivenin severe localized tissue reactions occured. 
In Costa Rica the polyvalent antivenin produced against the 
coral snakes Micrurus nigrocinctus and tl· al leni is also 
eFfective against the two other coral snake venoms, tl· 
Fulvius and tl· riarinicaudus dumerilii, however the 
antivenin provides no neutralizing capability against the 
venom rrom tl· mipartius (Bolanos et al ., 1975). The 
polyvalent antivenin can be userul in treating snakebite 
victims but variability in its neutralizing capabilities 
still exists. Ownby et al. (1986) have shown that Wyeth's 
polyvalent antivenin can neutralize the local myotoxic 
activity or Crotalus atrox venom, while having a poor 
capacity to neutralize the local myonecrosis induced by ~· 
y. viridis (Prairie rattlesnake) venom. In some cases 
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broad paraspecirity or snake antivenin has been round. 
Venoms rrom the Australian elapids, such as the tiger 
snake, death adder, and taipan may contain high 
concentrations or several important elapid toxins since 
antisera against them have extraordinarily broad paraspeci-
ric activity (Minton, 1967). Also, Sea Snake Antivenene 
has been shown to provide at least some protective errect 
against numerous elapid venoms, whereas elapid antivenins 
rail to neutralize sea snake venom (Minton, 1967). Cobra 
antivenins are largely genus speciric and show considerable 
variation in their neutralizing capacity. An extensive 
study conducted by Rosenreld and Kelen (1966) on the cross 
neutralization by antivenoms or the coagulant activity or 
snake venoms known to·have a direct coagulant activity 
showed that paraspeciric neutralization was round against 
venoms or the same genus and also or dirrerent genera. In 
ract the heterologous antivenom was sometimes more 
errective than the homologous antivenom. It is the 
hypothesis or Rosenreld and Kelen (1966) that related 
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snakes share several common components, and that some snake 
venoms are more antigenic than others. Thererore, the most 
antigenic venoms should be used ror the preparation or 
antivenoms since they provide the greatest protection 
against snakebite envenomation. 
Thus, antivenoms can prove to be an extremely bene-
Ficial treatment ror snakebite patients, providing the 
antiserum signiFicantly neutralizes the toxic errects or 
the snake venom, and also providing the patient is not 
sensitive to horse serum. The polyvalent antivenin 
commonly used in the United States is produced in the 
horse. In studies conducted by Alden (1969) and Russell et 
al. (1970) it was round that some patients requiring 
antivenin ror treatment or bites by venomous snakes were 
sensitive to horse serum. Russell et al. (1970) reported 
that with 241 cases or snake venom poisoning, 41 patients 
were round to have a slightly positive (1 to 2 plus) to 
markedly positive (3 to 4 plus) skin or eye test when 
exposed to horse serum. In those with a lesser reaction, 
Timmerman and Russell (1969) administered the antivenin as 
advised in the brochure accompanying the antivenin. 
However, this technique was found to be unsatisfactory 
since there was still some adverse reactions 
Improvement or antivenin therapy is an area that 
deserves attention since the treatment can produce variable 
results depending on numerous ractors. These variables 
include quantity and type or venom injected, quality of 
antivenin and also the sensitivity of the patient to horse 
serum. Keeping these facts in mind researchers have 
attempted to produce an improved antivenom, through 
purification of the antivenom (Timmerman et al ., 1969), 
production of monoclonal antibodies (Danse et al ., 1986; 
Kfir et al., 1986), and isolation and purification of 
specific venom components (Tan, 1983; Jeter et al., 1983; 
Ownby et al ., 1986). 
Advancements in antisera production 
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Recently advancements have been made in the production 
of an improved antiserum to treat local myonecrosis induced 
by snake venom of the Prairie rattlesnake (h. y.viridis) 
(Ownby et al., 1979; Ownby et al., 1986). Since the 
isolation of a pure myotoxin protein (myotoxin g), from the 
Prairie rattlesnake venom by Ownby et al. (1976) it has 
been possible to produce an antiserum specific to a pure 
myotoxic component of the snake venom (Ownby et al., · 1979). 
Myotoxin sis a small basic (isolectric point 9.8) 
polypeptide, consisting of 39 amino acids having 10 lysines 
and 1 arginine, and with a molecular weight of 4400 daltons 
(Ownby et al., 1976). The antimyotoxin serum produced by 
Ownby et al. (1979) has been shown to react with more than 
one crotalid venom using the Ouchterlony agar-gel double 
diffusion technique (Clausen, 1969). Since the titer of 
antimyotoxin in the commerical ly produced polyvalent 
(Crotalidae) antivenin is very low (Ownby et al., 1983b), 
it is possible to improve the treatment of local myonecro-
16 
sis by the addition or antimyotoxin serum (Ownby et al., 
1983a). Ownby et al. (1984) round that the amount or venom 
neutralized was twice that neutralize by the anti-myotoxin 
serum alone. Other snake venoms have also been reported to 
contain basic polypeptides responsible ror local myonecro-
sis (Gonvalves, 1956; Cameron and Tu, 1978; Leonardi et 
al ., 1979). The basic polypeptide (crotamine) isolated 
from Crotalus durissus terriricus venom resembles myotoxin 
chemically and also induces a local myonecrosis or skeletal 
muscle very similar to that caused by myotoxin ~(Cameron 
and Tu, 1978). Interestingly, Ownby et al. (1979) showed 
that antimyotoxin serum produced against the pure myotoxin 
protein of~-~· viridis venom can rorm a preciptitin line 
with some component round in ~. durissus terrificus venom, 
which is also identical to the line Formed between the 
myotoxin and antimyotoxin serum. ThereFore, it can be 
suggested that an antiserum produced to a pure venom toxin 
could improve the erricacy of a polyvalent antivenin and 
provide cross neutralization of specific deleterious 
eFfects, such as myonecrosis, due to snake envenomation. 
Tan (1983), who isolated a low molecular weight toxic 
fraction from venom of the Malayan cobra (Naja na.ia 
sputarix) and found the fraction accounted for almost one 
hundred percent of the venom's lethal activity. The 
antiserum produced against this lethal toxin was rour to 
eight times more potent than the commerical ly available 
Malayan cobra antivenin produced by immunizing horses with 
whole Malayan cobra venom. Reid (1964), for example 
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reported that in severe poisoning by very large doses or 
antivenom (100 ml) were required. The 1 imited 
neutralizing potency or the Malayan cobra antivenoms (0.2-
0.4 mg venom neutralized per ml or serum) may be due to the 
absence or antibody Formation against one or more lethal 
components or the venom (Tan, 1983). Lack or antibody 
Formation against speciric components or the venom may have 
various causes, including lack or antigenicity, low 
concentration or the speciric, lethal components and 
depression or antibody Formation by other antigens present 
in the venom in excessive amounts (Kochwa et al., 1959). 
Danse et al., (1986) have recently reported the rirst 
study on the neutralization capability or orBungarotoxin by 
monoclonal antibodies. Although there are numerous reports 
on the production or monoclbnal antibodies speciric to 
bacterial toxins (Hayakawa et al., 1983; Galloway et al., 
1984) there have been limited reports on the production or 
monoclonal antibodies speciric ror snake neurotoxins 
(Boulain et al ., 1982; Strong et al., 1984). The 
monoclonal antibodies produced against the post synaptic 
neurotoxin or Bungarus multicinctus (a-bungarotoxin) were 
round to neutralize the biological activity to varying 
degrees (Danse et al ., 1986). This is in agreement with 
results from other laboratories that round many monoclonal 
antibodies, but not all, can have an inhibiting erfect on 
the Function of the corresponding antigen (Mochly-Rosen and 
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Fuchs, 1981; Strong et al., 1984). However, the monoclonal 
antibodies did protect the mice against the toxic effect of 
a-bungarotoxin for a few hours to six days, depending on 
the selected monoclonal population. This is a considerably 
longer survival time than a period of seventy-nine minutes 
for the standard toxin dose. Although binding and kinetic 
studies have not been completed on the a-bungarotoxin and 
the monoclonal antibody interaction, the authors hypothe-
thesize that two factors may be influencing the lack of 
absolute protection by the monoclonal antibody. First, the 
affinity of the toxin for its receptor (acetylcholine 
receptor) may be greater than that of the antibody, or the 
antibody may be cleared at a faster rate than the toxin, 
which resists enyzmatic degradation and may be released in 
a still active state into the bloodstream (Danse.et al., 
1986). The first hypothesis may be valid for those anti-
bodies which neutralize the toxin for only a few hours, and 
the second hypothesis is consistent for the monoclonal 
antibodies which provide the greatest protection. 
Differences in affinities of the antibody for the toxin or 
in location of epitopes have also been suggested. 
Affinity Chromatography 
Affinity chromatography which can be classified as an 
adsorption chromatography is becoming increasingly popular 
among researchers for the separation of biological 
materials. The technique of biospecific affinity 
chromatography has been used for the isolation of enzymes, 
hormones, antibodies and other biologically active 
compounds (Cuatrecasas and Anfinsen, 1971). 
Prior to the use of affinity chromatography the 
majority of methods for the purification of biological 
substances were dependent upon gross physical and chemical 
differences between the· substances being separated (Gelb, 
1973). Gel filtration permits separation according to 
molecular size and shape. The principle of ion exchange 
chromatography is based on the electrical i.e. charge 
properties of the molecules. Affinity chromatography, 
however purifies biological substances based upon bio-
specific interactions between interacting pairs of 
substanc·es. The technique is rapid and specific, and 
permits isolation of a particular protein in a single step 
(Egorov, 1975). The biological interactions may involve 
the reaction between antibody and antigen, enzyme and 
inhibitor or hormone and carrier protein (Teouanne et al., 
1980). Regardless of the interacting pairs of substances 
the basis of separation remains based upon the biospecific 
interactions of the compounds 
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The affinity column is prepared by attaching one 
compound of the interacting pair to an insoluble matrix, 
which may be a cross-linked agarose gel bead or a 
polyacylamide gel matrix. A mixture of substances can then 
be applied to the affinity column. The compound within the 
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matrix that is capable or binding to the substance attached 
to the arrinity matrix is adsorbed to the column. The 
Forces involved in this binding reaction between the two 
compounds can include electrostatic, hydrophobic and Van 
der Waals interactions ·(Gelb, 1973). The adsorbed com-
pounds or compound depending upon the purity or the 
attached substance can be removed by changing pH (Sullivan 
and Russell, 1982) or ionic strength (Bureau and Daussant, 
1983). The adsorbed compound is then eluted while the 
immobilized protein remains attached to the arrinity 
matrix. The choice or eluant or eluants to remove the 
bound compound rrom the arrinity column depends in many 
instances up9n the nature or the interactions (Morgan et 
al., 1978). Once the adsorbed material has been removed 
the arrinity column can be regenerated by washing with the 
initial eluant. 
Arrinity PuriFication 
or Antibodies 
The use or arrinity chromatography ror the study or 
snake venom components (Gaebert, 1977), and ror the 
isolation or antibodies to speciFic toxins and snake venoms 
(Sullivan and Russell, 1983; Russell et al ., 1985; Kirchner 
and Faulstich, 1986) is becoming a growing area or 
research. Using arrinity chromatography Lomonte et al. 
(1985) isolated antibodies to a myotoxin round in Bothrops 
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asper venom. The affinity purified myotoxin antibodies 
were then used experimentally to treat local myonecrosis 
induced by the crude venom. The investigators were able to 
determine that the myotoxin of Bothrops asper is a major 
contributing factor of local myonecrosis, since the 
affinity purified antibodies neutralized a large amount of 
the myonecrosis caused by crude venom. Myonecrosis that 
was not neutralized probably was a consequence of local 
ischemia induced by the severe alterations of the microvas-
culatur (Gutierrez· et al., 1984). The purified antibodies 
could also be tested against numerous snake venoms by 
immunodiffusion. The antimyotoxin was used to test for the 
presence of immunologically related components in other 
snake venoms (Lomonte et al., 1985). Of the eleven 
different venoms tested onl~ one venom, Bothrops schlegel ii 
cross-reacted. Interestingly~- schlegel ii has also been 
shown to induce a type oF myonecrosis very similar to that 
caused by B. asper venom (Gutierrez and Chaves, 1980). 
Although the antibodies to Bothrops asper myotoxin were 
very efficient in neutralizing myonecrosis, they were not 
very effective in neutralizing the lethal effects of the 
venom. Similar results have been observed by Ownby et al. 
(1983a) using antimyotoxin serum to neutralize the local 
myonecrosis induced by ~- y. viridis venom. Myonecrosis 
was significantly reduced by the antimyotoxin serum but 
lethal effects of the venom were poorly neutralized. 
Affinity purification has also been used for the isolation 
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or antibodies speciric to neurotoxins. Cobrotoxin, a known 
neurotoxin rrom the venom or the Taiwan cobra (Naja naja 
atra) has been isolated by Yang (1965). It has proven to 
be the main toxic protein or cobra venom. Immunochemical 
studies conducted by Chang and Hayaskf (1969) on the 
cobrotoxin and its purfrfed antibody provides evidence that 
cobrotoxin has three antibody combining sites per molecule. 
Using arrinity chromatography Yang et al. (1977) puriried 
precipitating and non-precipitating antibodies to 
cobrotoxin. The neutral izfng capacities or the arfinity 
puriried antibodies were greater than that or the 
cobrotoxin antisera. Yang et al. (1977) round that the 
non-pre~ipitating antibodies had the ability to neutralize 
the toxic errects or the neurotoxin. However, Christian 
(1970) suggested that the railure or antibodies to 
precipitate may result from their 1 imited recognition or 
multiple antigenic determinants on complex antigens. One 
hypothesis that has been orrered regarding the biological 
difrerences between precipitating and non-precipitating 
antibodies is that non-precipitating antibodies are capable 
of binding with only a small number or antigenic 
determinants, lattice Formation or the antigen-antibody 
complex will be incomplete and, depending on the degree of 
its incompletion, the complexes wil 1 remain soluble in the 
precipitin reaction (Kabat and Mayer, 1961). Another 
hypothesis proposed to. explain why antibodies fail to 
precipitate with the specific antigen, include univalency 
or the antibody and low affinity or the antibody for the 
antigen (Yang et al., 1977). The non-precipitating 
antibody to cobrotoxin demonstrates, however an ability to 
neutralize the major toxic component or the venom. 
Therefore, caution must be taken when generalizing to the 
presence or non-precipitating antibodies and their effect 
on an antigen. 
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Tarng et al. (1986) have used affinity puriri~ation to 
isolate an endogenous antihemorrhagic Factor from the serum 
or the opos~um (Didelphis virginiana). Endogenous 
antihemorrhagic Factors From the sera or some snakes and 
warm blooded animals have been round to neutralize the 
hemorrhage activity or snake venoms (0vadia,~1978). Some 
or these factors have been isolated and characterized 
(Garcia and Perez, 1983). Arrinity chromatography ·or 
opossum sera by Tarng et al. (1986) has allowed the 
purification or antihemorrhagic Factors and permits the 
study or neutralization processes. Their results showed 
that affinity chromatography isolated the antihemorrhagic 
factor in a single step with an increase in the specific 
activity or the factor. 
Since affinity purification or biological substances 
is proving an eFFicient means to isolate specific desired 
proteins, the purification method has been experimentally 
tested to remove the extraneous protein content from 
commerically available antivenin. The extraneous protein 
is that portion or the antiserum not important in venom 
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neutralization, however it is orten times responsible ror 
sensitivity reactions, which include anaphylaxis (Sullivan 
and Russell, 1983). The commerical antivenin that was 
aFFinity puriFied so as to obtain an IgG Fraction was 
Wyeth's (Crotalidae) antivenin. Since this antivenin is 
commonly used throughout the United States to treat 
snakebite poisoning the results are or considerable 
clinical signiFicance. The composition or the commerical ly 
produced antivenin used in the experiment by Sullivan and 
Russell (1983) can best be described by a brier explanation 
or the process involved in the preparation or the polyval-
ent (Crotalidae) antivenin. One thousand milliters or 
crude serum are collected From horses immunized against a 
mixture or venoms consisting or ~. adamanteus (ea~tern 
diamondback rattlesnake), ~. atrox (westernback diamond 
rattlesnake), ~· dur~ssus terriricus (South American 
rattlesnake) and Bothrops atrox (Fer-de~Lance). The crude 
serum then is diluted in 2000 milliters or distilled water 
and 156 grams of ammonium sulFate are added per liter of 
serum. A precipitate which Forms overnight and consists or 
residual fibrin is then removed. One hundred and forty-
Four grams or additional ammonium sulFate are added per 
liter or serum, and a precipitate containing the active 
globulins is then collected. The precipitate is dialyzed 
to remove salts and later clariFied using centriFugation 
Finally a 0.85 percent sodium chloride solution is added 
and the antivenin is concentrated (Timmerman and Russell, 
1969). 
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Using affinity chromatography Russell et al. (1985) 
purified and concentrated the lgG fraction of the 
polyvalent antivenin and enhanced its efficacy. Affinity 
chromatography of the polyvalent antivenin eliminates the 
ammonium sulfate precipitation step, that proves to be 
costly and can result in the loss of neutralizing lgG. 
Also, ammonium sulfate co-precipitates many other serum 
proteins besides the desired lgG molecules, thus increasing 
the possibility of anal lergic reaction to the horse 
serum. 
The experimental protocol used by Sullivan and Russell 
(1982) and Russell et al. (1985) to purify the polyvalent 
antivenin involved the use of four different affinity 
columns. Coupled to each column was a single venom. The 
venoms chosen were ~- adamahteus, ~- atrox, ~- viridis 
hel leri (Southern Pacific rattlesnake) and ~- scutulatus 
(Mojave rattlesnake). The latter two venoms are not used 
in the production of commerically produced antivenin, 
however the antivenin provides good protection against 
these venoms. One vial of antivenin (10 milliters) was 
applied to each column. Each column was then eluted with 
phosphate buffered saline followed by glycine, pH 2.5. It 
was shown that the first peak contained the ext~aneous 
proteins and the second peak eluted by glycine, pH 2.5 
consisted of the purified lgG antibodies. Purified lgG's 
were then tested for their ability to provide protection 
against hemorrhage, lethal effects, fibrinogen clotting 
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activity and platelet aggregation activity induced by the 
four snake venoms. The results showed that for all 
parameters measured the affinity purified antibodies were 
more efficiacious than the commerical ly produced antivenin. 
In animals sensitized to horse serum the purified 
antibodies did not produce anaphylaxis or anaphylactoid 
reactions. Thus the affinity purified lgG antibodies 
provides an immunopharmacological agent, which offers 
protection against deleterious effects induced by crotaline 
venoms and does not cause a sensitivity reaction. 
It is therefore noteworthy that affinity chromato-
graphy is being applied to a wide range of toxins in venom 
research. The methodology offers to many investigators a 
rapid, sensitive and inexpensive means of purifying the 
toxin. The selective isolation and purification of 
biologically important macromolecules by affinity 
chromatography exploits the unique biological property of 
these proteins or polypeptides to bind ligands reversibly, 
therefore the potential usefulness of affinity 
chromatography, particularly in venom research, is 
virtually limitless. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
There has been a trend recently in the area of assay 
systems to move away from the more expensive radi"o~mmuno­
assays (RIA) involving isotopes, and therefore necessary 
precautionary steps, to the equally sensitive but 
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relatively inexpensive and versatile ELISA. ELISA does not 
require isotopes that orten have relatively short shelr-
1 ives or require special safety measures ror handling. The 
ELISA systems involve the use or antigens, haptens, or 
antibodies labelled with an enzyme to measure a variety or 
biological substances including, pit viper venoms (Minton 
et al., 1984) as well as antigens associated with parasitic 
diseases rrom a variety or geographical locations (Voller 
et al ., 1976). The assay systems have been given various 
names including enzyme-, enzymic-, enzymatic-, and enzyme-
immunoassay (Skelley et al., 1973). Enzyme-1 inked 
immunoassay, enzyme-labelled immunoassay, enzyme coupled 
immunoassay, immunoenzymatic assay, and enzyme-linked 
immunosorbent assay are synonymous (Wisdom, 1976). 
Types or ELISA 
Enzyme-immunoassay systems can be divided initially 
into two main categories, the heterogenous and homogenous 
assay systems. The majority or enzyme immunoassay systems 
reported in the literature rall into the heterogenous assay 
systems, since they prove particularly suitable ror the 
measurement or biological substances having a molecular 
weight or 10,000 daltons or more (Voller et al ., 1979). 
The homogenous enzyme-immunoassAy uses a hapten 1 inked 
to an enzyme, such that when the enzyme combines with the 
antibody the enzyme activity is altered. The test sample 
is allowed to react with enzyme-1 inked hapten Followed by 
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the addition oF the specific antibody. If the test sample 
contains any of the hapten it will combine with the 
antibody displacing the enzyme labeled hapten. Enzyme 
substrate is added to the mixture and any displaced enzyme 
label led hapten can degrade the substrate. The color 
change due to substrate degradation can then be read 
spectrophotometrical ly. The homogenous assay systems do not 
require any separation steps and can be performed within a 
matter of minutes. Therefore, the homogenous systems are 
being widely used to test for drug abuse as well as 
measuring therapeutic drug levels of digoxin, lidocaine and 
phenobarbital. 
Many researchers, however, Find the heterogenous assay 
system the method of choice. Heterogeno~s assay systems 
depend on the assumption that an enzyme can be linked to 
either an antigen or antibody while retaining both 
immunological and enzymatic activity (Voller et al., 1979). 
The heterogenous assay system in contrast to the homogen-
ous enzyme-immunoassays al 1 involve a separation step 
whereby the reacted enzyme-labelled component is separated 
·by washing it from the unreacted enzyme-labelled material. 
The types of heterogenous immunoassay systems can be 
divided into six categories. These categories are 1) the 
competitive method of ELISA for assaying antigen, 2) the 
double antibody method of ELISA for antigen detection, 
3) the modified double antibody sandwich ELISA for antigen 
detection, 4) modification of the indirect ELISA for assay 
29 
or antigen, 5) the indirect method For antibody detection 
and 6) solid-phase anti-IgM ELISA. 
Antigen Detection Methods 
The double antibody antibody sandwich ELISA is common-
ly used For antigen detection. The immunoglobulins or 
puriFied antibody are attached to the solid phase, Followed 
by a washing step. The test solution containing the 
antigen is added, then the plate is incubated and then 
washed. Enzyme labelled speciFic antibody to the antigen 
is added, washed, and Followed by the addition or enzyme 
substrate. The color change is proportional to the amount 
or antigen in the test solution. 
The ModiFied Double 
Antibody ELISA 
The modiFied ELISA For antibody detection varies From 
the double antibody systems in two important ways. The 
solid phase is coated with lgG or a puriFied antibody and 
test solution is added. Antibody speciFic to the antigen 
is again added, however now it is antibody produced in a 
diFFerent species From that coating the solid phase. Next 
an enzyme labelled anti-globulin is added and incubated, 
Followed by washing. The anti-immunoglobulins must be 
reactive with the immunoglobulin added in the second step 
but not react with the fmmunoglobul in used to coat the 
plate. The enzyme substrate is added and color change is 
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proportional to the amount of antigen in the samples. 
Indirect Method 
The indirect method permits the detection and 
measurement of antibodies. Specific antigen is attached to 
the solid phase which is later washed. The test solution 
is added, incubated and washed. Next the enzyme label led 
anti-globulin is added and allowed to react. Finally 
enzyme substrate is added and a color change occurs in 
antibody containing solutions. The amount and rate of 
color change is related to the amount of antibody present. 
ELISA and Toxin Research 
The application of ELISA to snake venom research has 
been reviewed by Theakston .(1983). Detection of the venom 
or some component of the venom, and the ability to detect 
antibodies administered against it are critical for 
improved treatment of snake bite envenomation. In many 
parts of the world, particularly the tropical countries of 
Africa, South America and Southeast Asia snakebite poses a 
major medical problem. The lack of a rapid, sensitive and 
inexpensive assay for venom detection often times prevents 
the proper treatment of snakebite cases~ The ELISA 
procedures most commonly adopted for snakebite studies are 
the indirect method for antibody detection and the double 
sandwich method for venom antigen detection. 
Recently Ho et al. (1986a) have critically appraised 
the applications of the ELISA in the study of snakebite. 
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In tropical countries where snakebite constitutes a major 
health problem, applying the immunodiagnosis technique or 
ELISA ror the treatment or snakebite envenomation may prove 
extremely helprul. However, Ho et al. (1986a) indicate the 
need ror an awareness or speciric problems unfque to ELISA 
and antigen-antibody detection. The major problems that 
are encountered with some ELISA systems are non-speciric 
reactivity, cross reactivity or the assay and the quality 
or reagents that can arrect both the assay's sensitivity 
and speciricity. Speciricity or venom antigen and antibody 
detection assays is generally taken as the lack or cross 
reactivity between closely related species (Theakston, 
1983). Non-specfric binding can also occur with normal 
serum samples. Greenwood and Whittle (1981) have reported 
a particularly high non-specfric reactivity associated with 
sera rrom people indigenous to the rural tropics. This can 
perhaps be explained by high levels or immunoglobulins, 
heterophile antibodies and rheumotoid ractor. These and 
other serum components can attach in a non-speciric manner 
to the solid phase or interact with reagents raised in 
other mammalian species. The seriousness or the problem or 
non-speciric binding has been shown by Ho et al. (1986a) 
in an epidemiological study conducted in Thailand. Using 
the indirect antibody detection assay their results 
indicated that seventy-rive percent or normal, healthy 
subjects had been bitten by the Thai cobra (Naja kaouthia) 
and had surrered surricient envenoming to elict an antibody 
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response. This figure implies that seventy-five percent of 
randomly selected normal individuals in eastern Thailand 
had to have been bitten on more than one occasion and yet 
had no history of signs or symptoms of envenoming. The 
percentage might more logically be explained as a non-
specific response by an indigenous population of the 
tropics. Theakston et al. (1981) have reported from 
epidemiological surveys conducted in Ecuador and Nigeria~ 
that snakebite victims had detectable levels of venom-
antibodies for as long as forty years after the bite. 
Their criteria for this conclusion was a cut-off absorbance 
value of 0.10, since it represented a visually detectable 
color change. However, Ho et al. (1986a) know of no other 
example of circulating antibodies persisting forty years 
after a single antigenic challenge. The arbitary cut-off 
value chosen by Theakston et al. (1981) may not be 
appropriate for such conclusions. 
Similar non-specific reactivity have been reported in 
the venom detection assay. Lwin et al. (1984) have shown 
the detection of venom in a number of patients in Burma, 
who had neither systemic or local signs of venom poisoning. 
In addition a persistant level of venom was found in 
patients that had received adequate antivenom therapy. 
Snake venom has been described as a mosaic of 
antigens, and common antigens have been shown in related 
and unrelated species, such as Elapidae and Viperidae 
(Kuekarni and Rae, 1956). Therefore, it is somewhat sur-
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prising that cross reactivity. another Factor to inFluence 
speciFicity, has not been a major problem in many snake 
venom assays (Coulter et al •• 1980). One hypothesis For 
this observation is that shared antigens are oF low 
antigenicity or are present only in minute amounts in whole 
venoms (Ho et al., 1986a). Partial cross reactivity in 
antibody detection is seen with snakes within the same 
subFamily and is complete among snakes oF the same genus. 
The use oF single venom components as antigens may reduce 
cross reactivity among species oF the same subFamily, but 
is unlikely to aFFect the detection oF antibodies to snakes 
oF the same genus, since they probably share many common 
antigens. Using antibody enzyme conjugates oF three 
individual pit viper venoms Crotalus atrox, Crotalus 
scutulatus scutulatus and A9kistrodon contortrix, Minton et 
al. (1984) were able to detect venoms oF most North 
American pit vipers at concentrations oF ten micrograms or 
less. However, species identiFication was not always 
possible. The speciFicity oF antigen detection can be 
improved with the preparation oF speciFic antibodies. 
Theakston et al. (1977) have recommended the use oF the 
ammonium sulphate precipitated fractions oF immune 
globulins. A comparison made by Ho et al. (1986a) oF the 
sensitivity of a double antibody sandwich ELISA for antigen 
detection using an ammonium sulphate preparation oF 
immunoglobulins was found to compare very poorly with that 
of lgG From the same antiserum purified by protein A 
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affinity chromatography. The increased sensitivity of the 
antigen detection assay obtained with the affinity purified 
IgG fraction allows the accurate measurement of smal 1 
changes in venom levels, which are especially useful for 
serial measurements of venom levels. 
Monoclonal antibodies to purified venom components 
should be in principle, the preparations of choice, how-
ever, they are often not available in field conditions or 
in rural areas, where snake bite cases are most likely to 
occur. In addition, monoclonal antibodies may have several 
disadvantages. Pukrittayakamee et al. (1983) have shown 
that in a competitive binding radioimmunoassay using a 
monoclonal antibody to factor X activator found in Thai 
Vipera russelli venom, that non-specific reactivity is a 
major problem even in antigen detection assays using 
monoclonal antibodies. One explanation for this occurence, 
is that monoclonal antibodies are not as avid as 
polyclonal antibodies. It may be that monoclonal 
antibodies do not adsorb well to plastic surfaces and in 
the case of enzyme labelling, the antibodies may in some 
way be altered. Whatever the explanation, it appears that 
an affinity purified polyvalent antibody permit$ an 
increase in assay sensitivity without an increase in non-
specific binding. 
Another method to decrease non-specific binding is by 
testing body fluids that are low in protein content, for 
example urine or wound aspirates (Ho et al ., 1986b). 
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Thirty-Four patients with systemic envenomation by the 
Malayan pit viper (Calloselasma rhodostoma) were tested by 
Ho et al. (1986b) using ELISA For the presence or venom in 
urine specimens, wound aspirates and blood samples. Urine 
tests were positive For eighty-seven percent, eighty-eight 
percent For wound aspirates and ninety-seven percent For 
blood samples. The presence or venom in urine specimens 
depends partially on the time elasped between the bite and 
admission to the hospital, and that in wound aspirates on 
the speed or dispersion or the venom From the bite site. A 
positive wound aspirate, however, is no prooF that systemic 
envenoming has occurred, and thereFore is less useFul as an 
indicator For therapy (Ho et al ., 198Gb). 
Minton et al. (1984) round in experiments with rats 
and mice envenomated by injection and natural bites that 
venoms or the pit vipers tend to stay localized near the 
site or injection, appearing in the blood and urine only 
when relatively large amounts or venom have been injected. 
Copperhead venom was detected at the bite site twenty-two 
hours aFter a sublethal bite, and in the urine three hours 
aFterwards. The copperhead venom, however, was not detect-
ed in the blood. Minton et al. (1984) tested numerous 
biological Fluids and tissues taken at autopsy For the 
presence or crotalid venom. Lung, trachael exudate and 
pleural Fluid showed the presence or venom more Frequently 
than peritoneal Fluid, kidney and brain. 
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The success of immunodiagnosis for the detection of 
snake venoms and antibody titers in various populations has 
encouraged researchers to develop an ELISA that would be 
suitable for field conditions. The ELISA procedure used in 
the laboratory requires the use of a spectrophotometer to 
determine the absorbance and can require a matter of hours 
to complete. These requirements which can easily be 
accomodated under experimental conditions, may however 
make the ELISA unsuitable for field conditions. Therefore, 
Chandler and Hurrell (1982) developed an enzyme immunoassay 
system suitable for field use. The snake venom detection 
kits were distributed to hospitals and laboratories. in 
Australia. The results indicated that an excellent 
correlation existed between clinical diagno~is, and 
detection and identification of snake venom in samples of 
blood, urine or bite site swab washings. 
The venom detection kit consists of six capillary 
tubes, each coated with rabbit IgG containing antibody 
against one of the five immunologically distinct Austral ian 
snake venoms (Sutherland, 1976). Each tube is joined by 
silicone rubber t~bing and connected to a one mil liter 
syringe. The test kit is the double antibody sandwich type 
ELISA for antigen detection, which involves the drawing in 
and explusion of the reagents provided in the kit. Briefly 
the steps required for venom detection are 1) drawing a 
sample, whole blood, urine or bite site fluid into the 
series of capillaries, 2) flush the sample out of the tubes 
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after ten minutes, wash with buffer, 3) add the mixture of 
rabbit anti-snake venom urease conjugates, 4) incubate ten 
minutes, wash the capillary tubes and 5) add enzyme 
substrate. A positive control capillary tube is included 
with each kit to indicate the color change to expect when 
venom is present in the test sample. Chandler and Hurrell 
(1982) found the kit was consistently capable of correctly 
detecting and identifying venom in samples containing at 
least fifteen micrograms per milliliter within a total of 
forty minutes. The lower limit could be reduced if 
incubation times were increased. Clinical specimens tested 
previously by RIA by Coulter et al. (1978) were correctly 
indentified by the ELISA if the concentration was ten 
nanograms per milliter or more. 
A qualitative enzyme immunoassay for the rapid 
clinical identification of snake venom is now also 
available in Australia .. Coulter et al. (1980) have 
developed an ELISA that is capable of detecting 0.5 ng/ml 
of crude snake venom in approximately ninety minutes or two 
nanograms crude venom in thirty minutes. Two factors 
contribute to the improved sensitivity of the clinical 
ELISA in comparison to the values obtained with the field 
detection kit. The clinical ELISA uses an incubation time 
that is slightly more than twice that required for the 
field kit, and the· incubation temperature used is .37 C in 
comparision to ambient temperature. The combination of the 
field kit available for venom detection and the clinical 
labortory ELISA has helped improve the diagnosis and 
treatment or snakebite patients in Australia. 
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The use or ELISA is not limited to venom detection in 
the 'field or venom research. Theakston and Reid (1979) 
used the indirect ELISA method (Theakston et al., 1977) 
'for screening antivenom potency. Antfvenom 'from three 
geographical regions were chosen to elvaluate 'for potency. 
The commerical antfvenoms tested were provided by West 
Germany, South Arrica and India. Antivenoms that had 
expired were also tested 'for potency. I nit i a 1 1 y r f ve 
median lethal doses (LDso> were injected into mice rol lowed 
by varying amounts or antivenom. The LDso is the dose or 
venom when injected into mice which will cause death in 
rirty percent or the population within twenty-four hours. 
Arter twenty-Four hours the neutralizing median errective 
dose (EDso> was determined. The EDso is the least amount 
or antfvenom needed to prevent the death in rirty percent 
or the mice tested. Thererore, the lower the EDso the 
higher the neutralizing capabilities or the antivenom. The 
optical densities 'for each dose or used antfvenom were 
tested using the ELISA system. Thus, a re-ference standard 
'for each antivenom was obtained and the EDSO determined in 
vivo was then compared to the optical density or the 
re-ference standard. Expired antivenoms had consistently 
low neutralizing potencies. Compared with the in vivo 
potency test ELISA is a rapid and simple test, however, at 
present an ELISA reference standard must be established 'for 
each commerical source of antivenom. 
More recently Gopalakrishnakone et al. (1981) have 
used the ELISA indirect method for the detection of 
antibodies to the lethal neurotoxin, crotoxin, from 
Crotalus durissus terrificus venom. Crotoxin is a complex 
of a basic phospholipase A2 and an acidic protein 
(Habermann and Breithaupt, 1978). 
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Gopalakrishnakone et al. (1981) raised antibodies in 
rabbits against the reconstituted crotoxin complex. An 
indirect ELISA method and immunodiffusion were used to test 
for a reaction of homologous and heterologous Crotalus 
toxins and venoms to the antiserum. The ELISA system 
proved to be the more sensitive detector of the antigen-
antibody reaction than immunodiffusion. Although the 
results given were qualitiative and not quantitative the 
indirect ELISA method clearly indicated a reaction of the 
antiserum to the a) crotoxin ·Complex b) homologous 
phospho! ipase Az, c) crotapotin, d) ~. g. terrificus 
venom, e) Mojave toxin and f) ~- horridus atricaudatus 
venom. The phospholipase A2 from elapid, hydrophiid, bee 
venoms or porcine pancreas showed no cross reaction with 
the antiserum used. The reaction of the antiserum between 
the crude venom (~. g. terrificus) and Mojave toxin from 
~. ~· scutulatus venom were the strongest and markedly 
similar. Crotoxin and Mojave toxin have both been shown to 
inhibit transmitter release from motor end terminals 
(Hawgood and Smith, 1977). The results obtained by 
Gopalakrishnakone et al. (1981) suggest a close antigenic 
relationship between these two lethal toxins. 
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CHAPTER III 
AFFINITY PURIFICATION OF ANTIBODIES 
TO MYOTOXIN A 
Introduction 
The use or good quality reagents in the enzyme-1 inked 
immunosorbent assay (ELISA) can improve the assay's 
sensitivity by decreasing non-speciric binding (Ho et al., 
1986a). Improved assay sensitivity has partially been 
accomplished by the protein A puriFication or the IgG 
rraction (Ho et al., 1986a). In addition, arrinity 
puriFication or antibodies to tetanus toxins and 
cobrotoxin yielded antibodies that provided improved 
neutralization to speciric deleterious errects induced by 
these toxins (Yang et al ., 1977; Lazarovici, 1984). 
Lomonte et al. (1985) have also used arrinity puriried 
antibodies to a myotoxin rrom Bothrops asper snake venom to 
erriciently neutralize localized myonecrosis. 
Since the antibody titer to the major myotoxic 
protein, myotoxin §, rrom Crotalus viridis viridis venom 
has been shown to be in low concentrations in the polyval-
ent (Crotalidae) Antivenin (Ownby et al., 1983b), the 
arrinity puriFication or antibodies to myotoxin 2 could 
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possibly be userul ror the improved neutralization or local 
myonecrosis induced by myotoxin s• and secondly would be 
extremely helprul in establishing sensitive antibody and 
antigen detection assays. 
Materials and Methods 
Myotoxin a 
Twenty-three milligrams or myotoxin s puriried by 
Ownby and Colberg (unpublished results) rrom Crotalus 
viridis viridis venom was coupled to an arrinity column. 
The myotoxin s was tested ror its biological activity on 
skeletal muscle in mice and ror its ability to interact 
with its speciric antibody in an enzyme linked-
immunosorbent assay (ELISA). 
Female mice (CD-1, Charles Rivers) weighing between 
24-25 grams were injected intramuscularly (i.m.) in the 
thigh with puriried myotoxin s (1.5 ~g/g). Twenty-rour 
hours rol lowing the injection the mice were killed by 
cervical dislocation and a sample or skeletal muscle rrom 
the injected thigh was taken and processed ror histologic 
study. 
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Immunodif"f"usion 
The Ouchterlony double-dif"f"usion technique (Clausen, 
1969) was used to test 'for a precipitin band between 
myotoxin ~ and antibodies in the crude serum. The tests 
were run 'for eight hours at room temperature using 1% 
agarose gels. Myotoxin §was tested-at a conentration of" 1 
mg/ml against crude serum obtained 'from three rabbits 
immunized against the antigen. Af"f"inity purif"ied antibod-
ies eluted with distil led water (OW), acetic acid (Hac) 
and phosphate buf"f"ered saline (PBS) were tested at a 
concentration of" 0.60 mg/ml against the myotoxin. A 
concentration of" 0.60 mg/ml is twice the concentration of" 
antibody used in a later experiment to test 'for 
neutralization of" myonecrosis. The antibody eluted with OW 
was tested also at a concentration of" 1.23 mg/ml. 
Antimxotoxin a serum 
Antimyotoxin § serum was produced as described by 
Ownby et al. (1979). Brierly, lyophilized myotoxin was 
dissolved in 0.85% NaCl and injected at a dose of" 0.25 
mg/kg into two 3 kg rabbits (New Zealand White). The 
rabbits were bled 'for pre-immune serum and subsequently 
injected with the myotoxin g. The myotoxin solution was 
emulsi-fied with an equal volume of" Freund's complete 
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adjuvant and 2.0m1 of the emulsion was injected intramus-
cularly between the shoulder blades. One week later a 
booster injection (2.0ml of an equal mixture of myotoxin 
and Freund's incomplete adjuvant) was given. Animals were 
bled at 1-2 week intervals with monthly booster injections. 
Serum from individual rabbits and bleedings was separated 
and stored separately at -20 C until used. 
Gel Filtration 
The lgG fraction of the antimyotoxin serum was 
isolated and used to develop an ELISA for detecting 
antibody to myotoxin 2· 
Dilutions of an IgG fraction containing antibodies to 
myotoxin were used to coat the ELISA microtiter plates and 
for a standard curve with the antigen and antibody 
detection ELISA systems, respectively. Affinity purified 
antibodies to myotoxin were later used for the ELISA 
detection systems once a sufficient quantity of antibody 
was affinity purified. 
Thirteen milliters of crude serum containing 
antibodies to myotoxin 2 were fractionated using an 
Ultrogel AcA-34 gel filtration column with PBS, pH 7.4 as 
the elution buffer. The IgG fraction was tested for anti-
body activity using the ELISA antibody detection system. 
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The IgG fraction was then pooled and concentrated to 1.34 
mg/ml with the Amicon ultrafiltration concentrating eel 1 
using a YM 10 membrane, exclusion limit 10,000 daltons 
(Amicon Corp. Danvers, MA). Micro-titer plates were coated 
with 1 ug/ml myotoxin ~, and dilutions (1:10, 1:25, 1:50, 
1:200, 1:1000 and 1:5000) of the IgG fraction were tested 
for the presence of antibodies to myotoxin ~ using the 
ELISA antibody detection system. 
The antimyotoxin obtained by gel filtration was also 
tested for its ability to bind myotoxin ~using an ELISA 
antigen detection system. Various concentrations of lgG 
and second antibody were tested for their ability to detect 
myotoxin 2· Initially microtiter plates were coated with 
either 0.50, 0.10 or 0.01mg/ml of the IgG fraction. A 
myotoxin 2 standard curve consisting of 100, 10, 2, 0.2 and 
0.1 ng/ml was then measured on the microtiter plates, which 
were coated with the different amounts of the lgG fraction. 
The concentration of second antibody (goat anti-rabbit) was 
kept constant at 1:2000. Secondly sample wells coated with 
O.Olmg/ml of IgG were tested for their ability to bind 
myotoxin 2 when the dilution of the second antibody was 
only 1:1000. 
Arrinity PuriFication or 
Antimyotoxin 
Antiserum against myotoxin a was produced in rabbits 
and puriried using arrinity chromatography. Twenty-Four 
grams or myotoxin a were conjugated to an Arri-Gel agarose 
gel bead support (Bio-Rad, Richmond, CA) ror 16 hours at 5 
C. The conjugated Arri-Gel was packed in a 1.5 em 
diameter, glass column to a height or 8.0 em. Prior to 
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application or the serum sample the column was equilibrated 
with phosphate burrered saline (PBS), pH 7.4. Samples or 
crude antiserum ranging rrom rive to twenty mil 1 iters were 
applied separately to the column at a rlow rate or 5 ml per 
hour, rol lowed by washing with PBS until the absorbance or 
the errluent returned to baseline. The absorbance or each 
tube was monitored with the LKB Unicord III recorder. The 
column was then eluted with distilled water (OW) until an 
intitial protein peak eluted. The elution was inter-
rupted for 12 to 24 hours arter which the elution with OW 
was resumed until the absorbance returned to baseline. The 
elution was continued with 25 mM acetic acid (Hac, pH 3.1) 
unti 1 another protein peak eluted. Finally the column was 
reequil ibrated with PBS until the absorbance returned to 
baseline. Al 1 protein peaks were measured at a wavelength 
or A280 nm with a OU-8 spectrophotometer and all Fractions 
47 
were also tested ror the presence or antibodies to myotoxin 
~ using the ELISA antibody detection system. 
Enzyme-Linked Immunosorbent Assay (ELISA). The 
antibody eluted with DW was used to develop an ELISA to 
detect antimyotoxin and myotoxin ~- The antibody detection 
assay was used to test ror the presence or arrinity 
puriried antimyotoxin in each rraction. Polystyrene 
microtiter plates (Flow Laboratories Inc., Mclean, VA) were 
coated overnight at 25 C with 1 ~g/ml with myotoxin g. The 
plates were washed the following day with washing buffer. 
Two-hundred microliters or known amounts (serial dilutions) 
of the IgG fraction containing antibodies to myotoxin gas 
previously determined, and 200 ul aliquots from each 
tube obtained by arrinity chromatography were added to the 
ELISA plate. All samples were incubated ror two hours at 
room temperature, then rinsed three times with washing 
buffer. Two-hundred microliters or goat anti-rabbit IgG 
alkaline phosphatase conjugate (Sigma Chemical Co., St. 
Louis, MO) were added to each well at a concentration of 
1:2000 and incubated for two hours at room temperature. 
The plates were again washed followed by the addition of 
the phosphatase substrate, p-nitrophenyl phosphate disodium 
(Sigma Chemical Co., St. Louis, MO). The substrate was 
allowed to react for thirty minutes. The amount or color 
formation is proportional to the antibody concentration in 
each sample. The absorbance for each wel 1 of the 
microtiter plate was read at a wavelength of 405 nm using 
an EIA manual reader. 
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An ELISA double sandwich antigen detection system was 
used to test the ability of the lgG fraction to bind 
detectable amounts of myotoxin ~- Microtiter plates were 
coated with 0.50, 0.10 and O.Olng/ml of the IgG fraction 
overnight at 4 C. The plates were washed the following day 
with washing buffer. All incubations of the coated 
microtiter plates were carried out at 37 C for two hours 
except for the substrate incubation which was performed at 
room temperature for thirty minutes. Two-hundred 
microliters of known amounts of myotoxin ~were added to 
each well. The dilutions of myotoxin ~· (1:10, 1:100, 
1:500, 1:1000, 1:5000 and 1:10,000) were made from a 1mg/ml 
stock solution of myotoxin. The microtiter plates were 
incubated and then rinsed three times with washing buffer. 
Two-hundred microliters of the lgG fraction (0.50, 0.10 and 
O.Olmg/ml) were added to each well, incubated and then 
washed. Two-hundred microliters of goat anti-rabbit IgG 
aklal ine phosphatase conjugate (Sigma Chemical Co., St. 
Louis MO) were then added to each well, incubated and 
rinsed three times. Finally, two-hundred microliters of 
phosphatase substrate, p-nitrophenyl phosphate disodium 
(Sigma Chemical Co., St. Louis, MO) were added. The 
amount of color formation is proportional to the antigen 
concentration in each sample. The absorbance for each well 
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of the microtiter plate was read at a wavelength of 405nm 
using and EIA manual reader . 
• Standard Curves. Antibodies obtained from each eluant 
{OW, Hac and PBS) were pooled separately. The pooled 
fractions were concentrated using an ultrafiltration 
concentrating eel 1 with a YM 10 membrane. A comparison of 
the ability of antimyotoxin eluted with OW, Hac and PBS to 
bind the purified myotoxin 2 was determined using ELISA. 
Antibody obtained with each eluant was diluted from 
10.0 to 0.10 ~g/ml and measured using the ELISA antibody 
detection system. Microtiter plates were coated with 
purified myotoxin 2 {1 ~g/ml). Two-hunderd microliters of 
antibody were added to each well except for those wells 
which received buffer alone. The wells having only buffer 
tested for non-specific binding. 
An antigen detection assay was also performed using 
the purified antibody. Microtiter plates were coated with 
1 ug/ml of affinity purified antibody eluted with either 
OW, Hac or PBS. Two-hundred microliters of known amounts 
of myotoxin §{50, 25, 20, 15, 10 and 5 ng/ml) were added 
to each well except for those wells which received buffer 
alone. 
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Neutralization of Myonecrosis by Affinity Purified 
Antimyotoxin. Affinity purified antibody to myotoxin ~ 
eluted with OW, Hac, and PBS was tested for its ability to 
neutralize local myonecrosis induced by myotoxin ~· Three-
hundred micrograms of affinity purified antibody obtained 
with each of the eluants and 750 ~g of myotoxin ~ were 
incubated together at 37 C for one hour and then centrifug-
ed. An aliquot of supernatant (0.050 ml) was injected 
intramuscularly ·(i.m.) into the thighs of individual mice. 
Female mice weighing 25 ± 0.50 grams, were divided into 
twelve groups, five mice per group. The twelve groups 
received the following treatments: 1) antibody from OW 
-fraction + myotoxin, 2) antibody from Hac fraction + myo-
toxin, 3) antibody from PBS fraction + myotoxin, 4) OW + 
myotoxin, 5) Hac + myotoxin·, 6) PBS + myotoxin, 7) anti-
body from OW fraction alone, 8) antibody from Hac fraction 
alone, 9) antibody from RBS fraction alone, 10) OW alone, 
11) Hac alone and 12) PBS alone. After twenty-four hours 
the mice were killed by cervical dislocation, a sample of 
skeletal muscle (primarily sartorius) from the injected 
thigh was removed and prepared for histology. 
Neutralization of Myonecrosis 
using Crude Antiserum 
Neutralization of myonecrosis using crude antisera was 
divided into two experiments. The rirst experiment tested 
the ability or antisera rrom two rabbits immunized against 
myotoxin 2 to neutralize two concentrations or antigen. 
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Experiment I. Antisera were incubated overnight at 4 
C with either 0.38 or 0.75 mg/ml or myotoxin. Control 
solutions consisting or a mixture (1:20) or pre-immune 
rabbit serum and 0.38 or 0.75 mg/ml or toxin were included 
in the experiment and treated the same as the antibody test 
solutions. The rol lowing day the solutions were centriruged 
and an aliquot (0.05 ml) rrom each supernatant was injected 
intramuscularly in the thigh or remale mice (CD-1 Charles 
Rivers) weighing 25 ± 0.50 grams. The doses or myotoxin a 
injected were 1.5 and 0.75 ~g/g. The experiment consisted 
or rive groups, rour mice per group. Arter twenty-rour 
hours the mice were killed by cervical dislocation and a 
sample or skeletal muscle (primarily sartorius) rrom the 
injected thigh was taken and processed ror histology. The 
neutralization or myonecrosis was determined by the 
myonecrosis index (Ownby et al ., 1982). 
Experiment II. Three ratios or-antigen:antiserum 
(1:10, 1:20 and 1:40) were tested ror their ability to 
neutralize local myonecrosis induced by 1.5 Mg/g or 
myotoxin. Control groups received or physiological saline 
(PSS) and toxin; pre-immune rabbit serum and toxin; 
antiserum alone; and PSS alone. A ratio or 1:20 For pre-
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immune serum and PSS to toxin was selected. The experiment 
consisted of seven groups, five mice per group. Mice 
weighed twenty-five grams. Mice were killed after twenty-
four hours and a muscle sample from the injected thigh was 
removed. The tissue was immediately processed and fixed 
for histology. 
Histological Preparation and 
Quantitation of Mvonecrosis 
Muscle samples from all neutralization experiments 
were taken from the injected thigh, cut into small pieces 
and placed in 2.5~ glutaraldehyde for two hours. The 
tissue was washed three times and fixed with osmium 
tetroxide for one hour. Next, it was dehydrated serially 
in ethanol, infiltrated with propylene oxide/polybed 812 
(1:1}, and embedded in polybed 812 resin, which was then 
polymerized by heating at 60 C for forty-eight hours. 
Thick sections (1 ~m} were obtained from a Sorvall MT 5000 
Ultramicrotrome stained with Mallory's trichrome. 
Five sections of muscle tissue per mouse were counted 
using a Zeiss light microscope equipped with a Zeiss MOP 3 
Image Analyzer. The number of vacuolated eel ls per total 
number of muscle cells was recorded to obtain a vacuolation 
index. 
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Results 
Myotoxin a 
PuriFied myotoxin 2 or Ownby and Colberg (unpub-
lished results) produced vacuolation or skeletal muscle 
cells typical For this toxin within twenty-Four hours aFter 
injection. No hemorrhage was observed. The puriFied 
myotoxin 2 was later used to establish the antigen and 
antibody detection assays. 
ImmunodiFFusion 
The toxin Formed a single precipitin band on the 
agarose gel plates when tested against.crude serum From 
rabbits immunized against myotoxin 2 (Figure 1). AFFinity 
puriFied antibody eluted with OW, Hac and PBS did not Form 
a precipitin band against myotoxin 2· 
Gel Filtration 
Figure 2 shows the IgG Fraction obtained with the 
Ultrogel AcA-34 column and the presence or antibodies to 
myotoxin 2 as determined by the ELISA antibody detection 
system. Dilutions or the lgG Fraction were tested using 
the antibody d~tection ELISA (Figure 3)~ Values with an 
absorbance reading at 280nm above 0.20 were obtained For 
the dilutions 1:10, 1:25, 1:50 and 1:200. Table I shows 
Figure 1. Ouchterlony agarose gel-diffusion plate. 
Center well: myotoxin g (1mg/ml). 
Peripheral wells 1,3 and 5 crude anti-
serum (AS-1) from a rabbit immunized 
with pure myotoxin 2 
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Figure 2. Gel Filtration or 13 ml crude antiserum 
containing antibodies to myotoxin 2 on an 
Ultrogel AcA-34 column. The sample was 
applied to a column that had been equili-
brated with PBS, pH 7.4 and eluted with 
the same burrer. A rive ml volume was 
collected per tube. The peaks were 
measured at A280 ror protein content and 
405nm ror antibody using ELISA. 
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Figure 3. Dilutions of an lgG fraction containing 
antibodies to myotoxin were tested with 
an ELISA antibody detection system. 
Microtiter plates were coated with l~g/ml 
myotoxin. Standard error bars are not 
present when they were too small to be 
visible. 
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TABLE I 
DETECTION OF A MYOTOXIN BY AN 
IgG FRACTION USING ELISA 
of' Myotoxin* Absorbance 
1 : 1 0 2> 
1 : 1 00 1.54 
1:500 1. 14 
1 : 1000 1.03 
1:5000 0.38 
1:10000 0.24 
1:1000000 nd 
IB** 0. 17 
405 (nm) 
+ 0.01 
+ 0.02 
+ 0.02 
+ 0.02 
+ 0.02 
+ 0.01 
* Dilutions of' myotoxin were made f'rom a 1.0mg/ml 
solution in incubation buf'f'er containing 1% BSA. 
** IB=incubation buff'er, 1% BSA, represents the 
background absorbance and it was subtracted f'rom all 
other absorbance values. Expressed as mean + stand-
ard error. nd= non detectable. 
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Figure 4. The affinity purification or 5 ml crude 
serum containing antibody to myotoxin § 
on an Affi-Gel 10 myotoxin § coupled 
column. Crude serum was applied to the 
column which had been equilibrated 
with phosphate buffered saline (PBS), pH 
7.4. The column was eluted initially 
with PBS followed by distil led water 
(OW). After a 12 h interruption the 
column was eluted again with OW, when 
baseline was reached the column was again 
washed with DW followed by acetic acid 
(Hac), pH 3.1. The final protein 
peak was obtained with PBS. The column 
was rinsed with PBS till baseline was 
again reached. A volume of Sml was 
collected per tube. All peaks were 
measured for protein content at A280 and 
antibody using ELISA at 405nm. 
0 
• tt) 
0 
• tt) 
(wu) sov aouoqJosqy 
0 0 0 
• • • N 
-
0 
.. 
"---
.) 
__ __, 0 
---- It') 
g 
:c 
-c::-
-----, 
<--
--~ 
---
-----=-- ---=-~ 
""""'-
--~=
---.,., 
" r ....,..-
------~ ,----
iS--
--.. 
) 
<......-1 _,_ __ _ 
0 
• N 
---....., 
0 
• 
-
I 
' ) 
l 
I 
(wu) osz eouoqJosqy 
0 
• 0 
0 
N 
-
62 
63 
the ability of the IgG fraction (O.Olmg/ml) to bind the 
myotoxin when a 1:1000 dilution of second antibody was 
used. Sample wells that were coated with 0.01mg/ml of IgG 
and received a 1:1000 dilution of goat anti-rabbit IgG 
(second antibody) were able to detect myotoxin g at a 
dilution of 1:10,000. However, regardless of the amount of 
lgG used (0.50, 0.10 and 0.01mg/ml) all absorbance readings 
were at or near background absorbance values if goat anti-
rabbit IgG was maintained at a 1:2000 dilution. Thus, 
different amounts of the lgG fraction used to coat the 
microtiter plates did not increase the sensitivity of the 
assay to detect myotoxin ~· However, the sensitivity of 
the antigen detection assay could be iricreased by using a 
more concentrated solution of second ·antibody. 
Affinity-Purification of 
Antibodies to Myotoxin a 
The affinity purification of five milliters of crude 
antiserum from a rabbit immunized with pure myotoxin ~ is 
shown in Figure 4. The initial peak or void volume had a 
large amount of protein as determined by A280 but only a 
small amount of antimyotoxin was detected when the 
fractions were measured with the antibody detection ELISA 
at a wavelength of 405 nm. The fractions of the void 
volume had an absorbance between 0.20 and 0.36 at 405nm, 
but an absorbance of almost 2.0 at 2aonm. Antibody to 
myotoxin g began to elute with the first washing with 
distilled water (OW). The interrupted phase of twelve 
hours followed by a second washing with OW yielded more 
antimyotoxin. A third washing with OW was tried but 
yielded virtually no antibody. This step was subsequently 
removed from the protocol. The final two elutions with 
acetic acid (Hac, pH 3.1) and phosphate buffered saline 
(PBS, pH 7.4) eluted a small amount of antimyotoxin. 
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Affinity purification of ten mill iters of crude serum 
from a rabbit immunized with pure myotoxin § is shown in 
Figure 5. The larger sample size yielded more antibody to 
myotoxin § in the OW, Hac and PBS peaks. However, the void 
volume also contained antibodies to the myotoxin as deter-
mined by the antibody detection ELISA. This finding 
suggest that the myotoxin coupled to the affinity column 
was saturated with its specific antibody, and the excess 
antimyotoxin enters the void volume with other serum 
proteins. Therefore, to efficiently use the affinity 
column the smaller sample size (5 ml) is desirable. 
Standard Curves. A comparison was made of the ability 
of antibodies to myotoxin eluted with OW, acetic acid and 
·PBS to bind myotoxin-coated microtiter plates. It was of 
interest to know if antibodies obtained with the different 
eluants interacted in a similiar manner with a known amount 
of toxin (l~g/ml), ie. provide similiar absorbance values. 
Table II shows the absorbance values at 405nm from an 
antibody detection ELISA using affinity purified antibody 
Figure 5. The a-ffinity purification of lOml crude 
serum containing antibody to myotoxin 2 
on an Arfi-Gel 10 myotoxin 2 coupled 
agarose column. The column was eluted 
initially with PBS, pH 7.4 followed by 
OW. Arter an interruption or 12h the 
column was again washed with OW, then 
Hac, pH 3.1. A volume or five ml was 
collected per tube. When baseline was 
reached the column was eluted with PBS 
followed by Hac and a final PBS elution. 
All peaks were measured 'for protein 
content at A280 nm and antibody at 405 nm 
using ELISA. 
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TABLE II 
DETECTION OF AFFINITY PURIFIED ANTIBODY ELUTED 
WITH OW, ACETIC ACID AND PBS USING ELISA 
{ug/m 1) * ow Acetic Acid PBS 
Absorbance 405 (nm) 
10.00 0.77 0.80 0.93 
7.00 0.79 0.63 0.90 
5.00 0.73 0.52 0.76 
3.00 0.55 0.48 0.54 
1.50 0.48 0.34 0.30 
1. 00 0.22 0. 13 0. 10 
0.50 0. 11 0.04 0.05 
0. 10 0.06 0.03 0.02 
IB** 0.12 0. 12 0.12 
Ab = affinity purified antibody eluted with 
acetic acid, pH 3. 1 ' or PBS, pH 7.4. 
ow, 
** IS = incubation buffer, 11. BSA represents back-
ground absorbance subtracted from all other absorbance 
values. 
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eluted with OW, Hac and PBS. The correlation coeFFicients 
for the OW, Hac and PBS standard curves are 0.87, 0.94 and 
0.94, respectively. The antibody eluted with OW was 
detected at lower concentrations compared to antibody 
eluted with Hac and PBS. The absorbance or 1 ~g/ml or OW 
eluted antibody was 0.224 compared to 0.130 and 0.098 ror 
antibody eluted with Hac and PBS, respectively. However, 
antibody eluted with Hac and PBS had higher absorbances at 
the higher concentrations of antibody when compared to 
antibody eluted with OW. 
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Table III shows the absorbance values ror myotoxin § 
using the aFfinity puriFied antibody with the antigen 
detection ELISA. Antibodies to myotoxin § eluted with OW, 
Hac and PBS-were able to detect 50 and 25 ng/ml or myotoxin 
E· Affinity purified antibody eluted with OW and Hac both 
had an absorbance value above 0.20 at 405 nm for 20 ng/ml 
myotoxin. The correlation coeFFicients ror the myotoxin § 
standard curves using arrinity puriFied antimyotoxin eluted 
with OW, and Hac are 0.99 and 0.97, respectively. 
Neutralization of Myonecrosis by Arrinity PuriFied 
Antimyotoxin. Table IV shows the myonecrosis indices 
obtained From mice injected with a mixture of toxin and 
affinity purified antibody. Myonecrosis was reduced in the 
presence or. antibody eluted with OW, Hac and PBS. The de-
crease in myonecrosis was greatest for mice treated with 
antibody eluted with OW. The decrease of myonecrosis for 
TABLE III 
MYOTOXIN A DETECTION (ELISA) WITH ANTIMYOTOXIN 
ELUTED WITH OW, ACETIC ACID AND PBS 
Solution* ow Acetic Acid PBS 
Absorbance (405 nm) 
IB 0. 124 0. 144 0. 160 
M-50 (ng/ml) 0.700 0.548 0.800 
M-25 (ng/ml) 0.312 0.265 0.475 
M-20 (ng/ml) 0.236 0.304 nd** 
M-15 (ng/ml) 0.,132 0. 153 nd 
M-10 (ng/ml) 0.088 0.152 nd 
M-05 (ngjml) 0.047 0.098 nd 
* I B = incubation bur 'fer, 1'1o BSA, represents back-
ground absorbance. Background was subtracted f"rom all 
other absorbance values. M = myotoxin 2 (ng/ml). 
** nd =not determined. PBS eluted a very small 
amount or protein. This peak was not used in later 
experiments. 
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TABLE IV 
NEUTRALIZATION OF MYONECROSIS BY AFFINITY 
PURIFIED ANTIBODY 
Treatment* Myonecrosis index** 
AbDW + Myo 7.7 + 1.8 
AbHac + Myo 3.7 + 2.4 
AbPBS + Myo 3.3 + 1.3 
Myo + ow 12.0 + 4.7 
Myo + Hac 7.6 + 1.7 
Myo + PBS 4.5 + 2.0 
AbDW + DW o.o 
AbHac + Hac 1.9 + 1.7 
AbPBS + PBS 0.0 
ow 0.0 
Hac 3.7 + 2.4 
PBS 0.0 
* Toxin and antiserum were incubated together at 37 
C for one hour. 0.05 ml of each solution was injected 
im into mice (n=5). Muscle samples were taken twenty-
four hours after the injection. Ab=antimyotoxin. DW= 
distil led eluant, Hac=acetic acid eluant, PBS=PBS 
eluant and Myo=myotoxin ~· The ratio of antibody to 
toxin is 300 ,ug:750 ,ug. 
** Myonecrosis index= number of necrotic 
cells/number of total cells expressed as mean+ stand-
ard error. 
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mice injected with toxin and antibody eluted with OW, Hac 
or PBS when compared to toxin alone provided indices or 
1.9, 3.9 and 2.3, respectively. Antimyotoxin eluted with 
OW, acetic acid and PBS reduced myotoxin §-induced 
myonecrosis, however it was not signiFicant (p<0.05). 
Control groups did not show any vacuolation or 
skeletal muscle. Mice treated with acetic acid alone did 
have some myonecrosis, however these muscle cells did not 
show the typical vacuolation induced by myotoxin §. 
Neutralization or Myonecrosis. 
Using Crude Antisera 
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Experiment I. Table V shows the amount or myonecrosis 
expressed as the myonecrosis index induced by two concen-
tratfons or myotoxin in the presence or absence or 
antisera. Myonecrosis induced by 1.5~g/g myotoxin §was 
reduced by the antiserum, however it was not signiFicantly 
diFFerent (p<0.05) when compared to the control group which 
received the toxin alone. The table also shows that 
antisera collected From two diFFerent rabbits both 
immunized with puriFied myotoxin §had diFFerent abilities 
to neutralize local myonecrosis caused by 0.75 ~g/g 
myotoxin. Antiserum (AS-1) did not-decrease the percent or 
myonecrosis induced by 0.75 ~g/g myotoxin, however AS-2 
slightly reduced the local myonecrosis induced by the same 
amount of toxin, but this was not signiFicant (p<0.05). 
TABLE V 
NEUTRALIZATION OF MYONECROSIS BY TWO CRUDE ANTISERA 
WITH TWO AMOUNTS OF TOXIN 
Treatment* Toxin (~g/g)** Myonecrosis 
index*** 
AS-1 
AS-1 
AS-2 
Prl 
Prl ) 
1.50 
0.75 
0.75 
~.so 
0.75 
3.3 + 1.6 
4.9 + 1.8 
2.6 + 1.3 
10.6 + 3.4 
2.9 + 0.7 
* Antisera (AS) was combined with the toxin at a 
1:20 dilution. An amount of 0.05 ml was injected into 
25 + O.SOg mice. Prl= pre-immune serum. 
** Toxin = myotoxin § 
*** Myonecrosis index = number of necrotic 
cells/number of total cells. Expressed as mean+ 
standard error (n=4). 
72 
73 
Experiment II. Table VI shows the amount or local 
myonecrosis induced by myotoxin ~ (1.5 ~g/g) in the 
presence or 1:10, 1:20 or 1:40 crude serum containing 
antibodies to myotoxin ~· Myonecrosis between groups 
receiving diFFerent amounts or antisera was not 
signiFicantly diFFerent (p<0.05). Control mice receiving 
pre-immune serum and toxin had a higher myonecrosis index 
than mice receiving PSS and toxin, however it was not 
statistically signiFicant (p<0.05). All groups receiving 
antiserum had less myonecrosis when compared to the control 
group which received pre-immune serum and toxin. The 
decreases in myotoxin ~-induced myonecrosis were not 
signiFicant (p<O.O~). 
Discussion 
AFFinity puriFied antisera to myotoxin ~ did not 
signiFicantly decrease (p<0.05) myotoxin a-induced myo-
necrosis. Crude antisera contained precipitating 
antibodies that are capable or decreasing the percent 
myonecrosis induced by 1.5 ~g/g, however in the presence or 
0.75 ugjg toxin did not signiFicantly (p<O.OS) decrease 
myonecrosis. This may be due to the Fact that at lower 
concentrations or toxin, detection or myonecrosis at the 
level or the light microscope is not always possible. 
Thus, changes in the amount or myonecrosis due to the 
presence of the antiserum are also more diFFicult to 
detect. Interestingly, increasing amounts of crude 
TABLE VI 
NEUTRALIZATION OF MYONECROSIS BY A CRUDE 
ANTISERUM AT THREE DILUTIONS 
Treatment* Toxin (ug)** Myonecrosis 
index*** 
AS (1:10) 1. 50 8.5 + 3. 1 
AS ( 1 :20) 1.50 12.3 + 4.8 
AS (1:40) 1.50 10.6 + 3.0 
PSS 1.50 6.3 + 1.9 
Prl 1.50 11.6 + 3.8 
AS 0.00 0.0 
PSS 0.00 0.0 
* 0.05 ml or each solution was injected intra-
muscularly into a group or mice (n=5). Muscle samples 
were taken twenty-rour hours arter the injection. 
PSS =physiological saline, AS= antiserum, and Prl = 
pre-immune serum. 
** Toxin = myotoxin g 
*** Myonecrosis index = number or necrotic 
eel ls/number or total cells. Expressed as mean+ 
standard error (n=5). 
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antisera did not neutralize more myotoxin g_-induced 
myonecrosis. Ownby et al. (1983a) have observed that 
myotoxin g_ plus horse serum induces more myonecrosis than 
toxin and physiological saline (PSS). This is consistent 
with the results obtained in this study, which shows not 
only more myonecrosis when toxin and pre-immune serum are 
injected, but also an increase in myonecrosis with 
increasing amounts or crude antiserum. The possibility 
exists that some component in the crude serum acts to 
enhance the activity or the toxin by increasing its binding 
to skeletal muscle. 
Following arrinity puri-fication or the crude antiserum 
non-precipitating antibodies were obtained. The presence or 
non-precipitating antibodies in antiserum has been 
recognized ror quite some ~ime, however the exact nature 
and role or these antibodies are still not completely 
understood. Christian (1970) has suggested that a limited 
recognition or multiple antigenic determinants may result 
in a 'failure or antibodies to precipitate. It has also 
been suggested that non-precipitating antibodies may be low 
arrinity antibodies (Yang et al., 1977). Although, Yang et 
al. (1977) have reported the isolation or a non-
precipitating antibody to cobrotoxin using a column or 
cobrotoxin-Sepharose, a technique requiring antibody or 
high arrinity. It may be that our antibody has a 1 imited 
recognition or.the antigenic epitopes or myotoxin g_ or is a 
low arfinity antibody. 
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The largest percent or our antibody was eluted under 
gentle conditions. Bureau and Daussant (1983) have 
successrully used desorption or an antigen using distilled 
water and an interrupted phase rol lowed by distilled water. 
However. the arrinity or the antigen ror its antibody was 
not tested. Using the ELISA detection system it is 
possible to obtain some idea or the arrinity or an antibody 
ror its speciFic antigen (Lew, 1984}. Since the arrinity 
or an antibody ror its antigen can be extemely varied Lew 
(1984) has suggested that ELISA be used as a qualitative or 
semi-quantitative test. A high arrinity antibody can 
detect antigen or less than one nanogram when an antigen or 
high epitope density is used, however a low arrinity 
antibody may be sensitive to levels only greater that two 
micrograms per mil 1 iter (Lew, 1984). Our ELISA results 
also show dirrerences in antibody sensitivity ror its 
antigen depending-upon whether the antibody was eluted with 
OW, Hac or PBS. Antibody eluted with PBS, the rinal 
eluant, had the highest absorbance readings ror both the 
antibody and antigen detection assays, however it proved 
the least errective in neutralizing myonecrosis. Since the 
PBS peak yielded a very small amount or antibody it was not 
possible to test the antibody eluted with this burrer ex-
tensively. The initial antibody peak which was eluted with 
DW may be a lower arrinity antibody, as suggested by its 
lower absorbance readings For both the antigen and antibody 
ELISA's, this however does not preclude the hypothesis that 
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the antibody recognizes and binds to the antigenic epitope 
on the myotoxin located in the active site or the molecule. 
Antibody to myotoxin ~obtained by gel Filtration was 
not tested ror its neutralizing capabilities, however the 
antimyotoxin or the lgG Fraction did bind to the puriFied 
antigen in the antibody detection ELISA. Our IgG fraction 
(O.Olmg/ml) was quite capable or detecting myotoxin ~' 
however it was critical that the second antibody was used 
at a dilution or 1:1000. The IgG Fraction was able to 
detect very small amounts or antigen (1:10,000 or 0.1ng/ml 
myotoxin). Ho et a1.(1986a) have also reported an increase 
in sensitivity ror the double antibody sandwich ELISA using 
an lgG puriFied by protein A arrinity chromatography. The 
increased sensitivity of the antigen (Calloselasma 
rhodostoma) detection ELISA allowed ror the accu~ate 
measurement or small changes in venom levels. It may be 
correct to assume that Ho et al. (1986a) had a higher 
aFfinity antibody than our antimyotoxin, since the amount 
or IgG used to coat their microtiter plates was as low as 
1-2 pg/ml lgG compared to our 0.5-0.0lmg/ml lgG. 
In conclusion, antibody to myotoxin ~ has been 
arrinity puriFied and tested for its ability to bind the 
antigen "in vitro" using the 1) antibody detection ELISA, 
2) antigen detection ELISA and ''in vivo" 3) by measuring 
the myonecrosis index of mice injected with a mixture or 
aFfinity purified antimyotoxin and myotoxin ~· The latter 
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results have been compared to the ability of crude antisera 
to neutralize myotoxin g-induced myonecrosis. Affinity 
purified antibody cannot neutralize myonecrosis, although 
slight differences in the myonecrosis index were observed 
between antibodies eluted with OW, acetic acid and PBS. In 
addition affinity chromatography removes extraneous 
components of the crude serum which appear to enhance local 
myonecrosfs. Importantly, the affinity purified antibody 
to myotoxfn 2 was useful in establishing antigen and 
antibody detection ELISA systems that proved helpful in 
later investigations. 
CHAPTER IV 
THE 1M VIVO DISAPPEARANCE OF ANTIBODY TO 
MYOTOXIN A FROM THE BLOOD 
Introduction 
ELISA is playing an important role in the development 
oF Field tests For the rapid identiFication or the snake 
venom in specimens such as blood, urine or bite-site swab 
-washings (Chandler and Hurrell, 1982; Dhaliwal et al., 
1983). In addition, ELISA has also been used as an 
epidemiological tool to detect the presence or venom-
antibodies in human snakebite victims from the region of 
Bambur, Nigeria (Theakston et al., 1981) and to detect 
circulating antibodies in subjects living in epidemic 
yellow rever areas (Deubel et al ., 1983). Clinical studies 
suggested that venom-antibody titers too low to be detected 
by ELISA, may be boosted with further bites, and the 
homologous venom-antibody may aFford significant protection 
against Further poisoning (Theakston et al., 1981). More 
recently Lwin et al. (1984) and Ho et al. (1986b) have 
used the ELISA antigen (Vipera russel i and Cal loselasma 
rhodostoma) detection system in a clinical setting to 
monitor venom levels. The ELISA has proved particularly 
useFul in these investigations since persistant high blood-
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venom levels may indicate the need ror more antivenin or 
suggest that the antivenin being administered is 
inerrective. However, the use or ELISA to monitor blood 
levels or administered antibody has not been studied. 
Currently decisions to administer more antiserum are based 
in part on the blood level or venom rather than antiserum 
(Ho et al., 1986b). Although it is extremely userul to 
detect blood-venom levels, the need to monitor blood-
antibody levels is critical. 
In the United States numerous crotaline venoms have 
been shown to share a speciric deleterious protein, 
myotoxin g (Chapter VI) that is known to induce local 
myonecrosis (Ownby et al ., 1984b). An antiserum has since 
been produced against the myotoxin that is capable or 
neutralizing the local myonecrosis. 
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Thererore, an experiment was perrormed to study the 
disappearance or antibodies to myotoxin g rrom blood over a 
rour week period. The dirrerence in rate or disappearance 
or antibody ror dirrerent concentrations or antiserum was 
also studied. An ELISA antibody detection system was used 
to detect and monitor blood levels or antibody to myotoxin 
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Materials and Methods 
Antibody Detection ELISA 
Ninety-six wel 1 Flat bottom microtiter plates (F.low 
Laboratories, Mclean, VA) were coated with 1 ~g/ml or puri-
Fied myotoxin g. The myotoxin g was diluted with coating 
buFFer, pH 9.6 (1.59g Na2C03, 2.93g NaHC03, 0.20g NaN3, lg 
bovine serum albumin, BSA dissolved in one liter distilled 
water). Two-hundred microliters or 1 ~g/ml myotoxin g were 
added to each well and incubated overnight at 4 C. The 
rol lowing day the microtiter plates were rinsed three times 
with washing burrer (45.0g NaCl, 2.5ml Tween-20 dissolved 
in 5 liters distilled water). The plates were allowed to 
soak rive minutes between each rinsing. Following the 
Final rinsing, two-hundred microliters or either known 
concentrations or antibody or blood samples were added to 
each well. The antibody solutions ror the standard curve 
were diluted with incubation burrer (900ml phosphate 
buFFered saline, PBS pH 7.4, 0.45ml Tween-20, 0.18g NaN3 
and 1g BSA) The antibody standard solutions consisted or 
the rol lowing concentrations 500, 400, 200, 100, 50, 25, 10 
and 5 ng/ml. Four wells coated with myotoxin g received 
two-hundred microliters or incubation burrer alone contain-
ing 11. BSA and were assayed For non-speciFic binding. Al 1 
samples were incubated For two hours at room temperature. 
Arter the incubation period the plates were rinsed three 
times with washing burrer. Following the Final rinsing 
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two-hundred microliters of goat anti-rabbit lgG (Sigma, St. 
Louis, MO) at 1:2000 dilution were added to each well. 
Goat anti-rabbit IgG was diluted in incubation buffer 1% 
BSA. The plates were again incubated for two hours at room 
temperature and following the two hour incubation the 
plates are again rinsed. Two-hundred microliters of 
phosphatase substrate (p-nitrophenyl phosphate disodium, 
Sigma, St. Louis, MO) were then added to each well. The 
phosphatase substrate was diluted to 1 mg/ml in 
diethanolamine buffer, pH 9.8 (9.7ml diethanolamine, Sigma, 
St. Louis, MO, 80ml distilled water, 10.0 MgC12, 0.02g 
NaN3). The substrate was allowed to react for thirty 
minutes at room temperature and the reaction was stopped 
with O.OSOml 3N NaOH. Absorbance of each wel 1 was measured 
at 405nm with an EIA manual reader. The amount of color 
formed is proportional to the amount of antibody present in 
each sample. Absorbance values (405nm) were converted to 
concentration (ng/ml) of antibody using the standard curve 
of that plate. 
Disappearance of Crude Antiserum 
Crude antiserum was injected instead of affinity 
purified antibody for two important reasons. Ownby et al. 
(1983a) have shown this crude antiserum capable of 
decreasiing myotoxin §-induced myonecrosis, thus these are 
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two-hundred microliters of goat anti-rabbit lgG (Sigma, St. 
Louis, MO) at 1:2000 dilution were added to each well. 
Goat anti-rabbit lgG was diluted in incubation buffer 1% 
BSA. The plates were again incubated for two hours at room 
temperature and following the two hour incubation the 
plates are again rinsed. Two-hundred microliters of 
phosphatase substrate (p-nitrophenyl phosphate dfsodium, 
Sigma, St. Louis, MO) were then added to each well. The 
phosphatase substrate was diluted to 1 mg/ml in 
diethanolamine buffer, pH 9.8 (9.7ml diethanolamine, Sigma, 
St. Louis, MO, 80ml distilled water, 10.0 MgCl2, 0.02g 
NaN3). The substrate was allowed to react for thirty 
minutes at room temperature and the reaction was stopped 
with O.OSOml 3N NaOH. Absorbance of each well was measured 
at 405nm with an EIA manual reader. The amount of color 
formed is proportional to the amount of antibody present in 
each sample. Absorbance values (405nm) were converted to 
concentration (ng/ml) of antibody using the standard curve 
of that plate. 
Disappearance of Crude Antiserum 
Crude antiserum was injected instead of affinity 
purified antibody for two important reasons. Ownby et al. 
(1983a) have shown this crude antiserum capable of 
decreasiing myotoxin §-induced myonecrosis, thus these are 
antibodies known to neutralize myonecrosis. Secondly, the 
amount of affinity purified antibody available was not 
enough to permit an ln vivo experiment. 
Female mice (CD-1, Charles Rivers, MA) weighing 25 + 
0.5g were divided into six groups, five mice per group. 
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The six groups consisted of mice receiving intravenous 
injections (i.v.) of 1) O.lOml crude antiserum, 2) 0.10ml 
physiological saline (PSS), 3) 0.15ml crude antiserum, 4) 
0.15ml PSS, 5) 0.20ml crude antiserum and 6) 0.20ml PSS. 
Crude antiserum was obtained from a rabbit immunized 
against myotoxin § and tested on a 1% agarose gel diffusion 
plate for a single precipitin band. All injections were 
given into the tail vein and blood samples (0.04ml) taken 
with a capillary tube were diluted with 0.960ml of PBS 1% 
BSA. Blood samples were taken immediately (zero time), and 
0.5, 1, 3, 6, 12, 24, 48, 72, 96h, 2 and 4 weeks following 
the injections. A two-hund.red microliter aliquot from each 
blood sample was assayed in duplicate using the antibody 
detection ELISA system. Dilutions of the affinity purified 
antimyotoxin § were used for the standard curve and assayed 
with each microttter plate. Also, sample wells coated with 
antigen and receiving incubation buffer instead of 
antimyotoxin § were always included to test for non-
specific binding. 
Results 
Antibody Detection ELISA 
Figure 6 shows a flow chart of the steps involved in 
the antibody detection assay. Our ELISA plates had 
Figure 6. A Flow chart illustrating the steps involv-
ed in the antimyotoxin detection. ELISA. 
ELISA FOR ANTI-MYOTOXIN a DETECTION 
1. MYOTOXIN a 0 ADSORBED TO PlATE 
WASH 
.... 
2. SOLUTION CONTAINING ANTI-MYOTOXIN a 
WASH 
.... 
A ADDED. 
3. ALKALINE PHOSPHATASE LABELLED 
ANTIBODY TO RABBIT lgG E ADDED 
WASH 
.... 
E-c=vE 
4. ENZYME SUBSTRATE 0 ADDED 
~. READ ABSORBANCE OF REACTION 
PRODUCT 0 AT 405nM 
£ 
l·-t&-·1 
0 0 
l ~-qy~, 
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extremely low non-specific binding with absorbance readings 
slightly above 0.10. Table VII shows the absorbance 
readings for three standard curves using known amounts of 
affinity purified antibody. The correlation coefficients 
of the three standard curves are 0.91, 0.97 and 0.96. The 
small differences between duplicate samples are reflected 
in the small standard errors. Differences in absorbance 
readings for the same amount of antibody assayed on 
different plates are due at least in part to differences 
between ELISA microtiter plates. Regardless of the plate 
used the non-specific binding was never above 0.121. 
Disappearance of 
Crude Antiserum 
Figures 7, 8 and 9 show the disappearance of 
antimyotoxin following the injection of 0.10, 0.15 and 0.20 
crude antisera, respectively. The pattern of antimyotoxin 
disappearance for each group was very similar. Blood levels 
of antibodies to myotoxin for each group decreased sharply 
three hours following the injection of antiserum. A slight 
increase in the level of blood antimyotoxin occured at six 
hours for each group. However, blood levels of antimyo-
toxin gradually decreased at 12, 24, 48, 72 and 96h until 
antibody was no longer detected at two and four weeks. At 
24, 48, 72 and 96h blood levels of antibody to myotoxin 
were very similar among treatment groups. The mice 
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TABLE VI I 
DETECTION OF ANTIMYOTOXIN USING ELISA 
Ab (ng/ml )* Plate 1 Plate 2 Plate 3 
Absorbance 405 (nm) 
500 0.439 + • 0 1 0.687 + .02 0.568 + .02 
400 0.502 + .02 0.462 + • 0 1 0.505 + .02 
-. 
200 0.403 + • 0 1 0.357 + • 0 l 0.393 + .03 
100 0.270 + . 0 1 0.229 + ."0 1 0.225 + • 0 l 
50 0. 1 1 1 + • 0 1 0. 173 + .00 0.239 + • 0 1 
25 0.075 + • 0 1 0. 198 + • 0 1 0.062 + .00 
10 0.031 + • 0 1 0.028 + • 0 l 0.027 + • 0 1 
5 0.023 + • 0 1 0.024 + • 0 1 0.024 + .02 
IB** 0. 1 16 + .004 0. 12 1 + .008 0. 1 1 9 + .002 
* Ab = affinity purified antibody obtained with the 
ow eluant. The antibody st.andard curve was assayed on 
three different microtiter plates. A 1 1 samples were 
assayed in dup 1 i cate. Expressed as mean + standard 
error. 
** IB = incubation buffer 11. BSA. Sample we l 1 s were 
coated with antigen and IB was assayed for non-
specific binding. The background values have been 
subtracted from each absorbance r~ead i ng. 
Figure 7. Graph showing the disappearance o~ anti-
myotoxin ~ ~rom the blood o~ mice using 
the antibody ELISA detection system. 
Each po·int represents the mean o~ ~ive 
mice. Mice were injected (i.v.) with 
O.lOml crude antiserum. 
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Figure 8. Graph showing the disappearance or anti-
myotoxin rrom the blood or mice using the 
antibody ELISA detection system. Each 
point represents the mean or rive mice. 
Mice were injected (i .v.) with 0.15ml 
crude antiserum. 
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Figure 9. Graph showing the disappearance of anti-
myotoxin From the blood oF mice using the 
antibody detection system. Each point 
represents the mean of five mice. Mice 
were injected (i.v.) with 0.20ml crude 
antiserum. 
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injected with O.lOml antiserum had the lowest blood levels 
or antimyotoxin, and as might be expected the 0.20ml or 
crude antiserum had the highest absorbance values during 
the ninety-six hour sampling period, but decreased to non-
detectable levels at two and Four weeks identical as in the 
0.10 and 0.15ml crude antiserum treated groups. Blood 
samples taken rrom the control groups had low background 
absorbance readings, 0.10-0.20. 
Discussion 
Blood levels or antibodies to myotoxin ~have been 
monitored over a Four week period using ELISA. Although 
care must be taken when extrapolating results between 
laboratory animals and human snakebite victims, our results 
indicate a rapid clearance or antibody From the blood in 
al 1 groups, particularly within the First three hours. 
Regardless or the amount or antiserum injected within three 
hours or less the blood-antiserum levels had decreased by 
at least rirty percent when compared to zero time. Blood 
levels or antimyotoxin were very similar between treatment 
groups at 24, 48, 72 and 96h indicating that the amount or 
antiserum injected did not signiFicantly alter its 
disappearance. By two weeks the antiserum had completely 
cleared From the bloodstream in al 1 groups. Thererore, the 
errect or time on the rate or disappearance or anti"myotoxin 
from the blood seems to play a more important role than the 
amount or antiserum injected. 
It is particularly noteworthy that arter only twenty-
four hours the blood levels of antimyotoxin had decreased 
seventy percent, when compared to zero time. It is also 
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important to keep in mind this rapid decrease in blood 
levels or antibodies to myotoxin was observed in the 
absence or toxin. The presence or toxin is certain to 
increase the rate of disappearance of the antiserum From 
the blood (Chapter 5). Clinically the low levels of 
antibodies to myotoxin observed at 24h (as well as 48, 72 
and 96 hours) are critical since such low concentrations or 
the antibody would probably not neutralize the myotoxic 
effects or the venom. 
Ownby et al. (1976) have reported the sequence or 
degenerative events in skeletal muscle cells roll0wing an 
intramuscular injection or 1.5~g/g or pure myotoxin ~­
Their results show that partial vacuolation of muscle cells 
occur at 6, 12 and 24 hours and complete vacuolation and 
loss or striations at 48 and 72 hours. Thus, the degenera-
tive eFfects induced.by myotoxin occur over a matter of 
days. It is therefore, logical that a neutralizing level 
of antiserum must be sustained for perhaps days to properly 
treat myotoxin ~-induced myonecrosis. 
Ho et al. (1986b) have used the venom detection ELISA 
to monitor changes in blood-venom levels. The results·of 
their assays were then used in part to decide upon further 
treatment. If blood-venom levels remained elevated or 
showed a tendency to increase, adminstration of more 
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antivenin was considered. The same rationale can be 
applied when monitoring blood-antivenom levels. High 
levels or blood-antivenom would indicate additional 
antivenom is not required, conversely low or non-detectable 
blood-antivenom levels indicate the need ror more 
anti venom. 
Closer attention must also be given to blood levels or 
crude antiserum especially since it is known that the 
administration or antiserum can result in Further 
complications ror the snakebite victim, such as serum sick-
ness (Loprinzi et al., 1983; Jeter et al., 1983). Investi-
gators (Russel 1 et al ., 1970; Kocholaty et al ., 1971) have 
produced an antivenin in goats rather than horses as a 
means to avoid the allergic response seen in some patients 
to horse serum. However, the use or the ELISA to monitor 
blood levels or the antiserum may help minimize the aller-
gic response seen in some patients by avoiding unnecessary 
administration or the antivenin and also indicate the time 
more antiserum should be administered. 
In conclusion this current study provides important 
inFormation regarding the disappearance or antibodies to 
myotoxin rrom the bloodstream, which has not previously 
been available. The level or antibodies to myotoxin 
decreases rapidly within the First three hours, gradually 
declining to low concentrations at 24, 48, 72 and 96h. 
These results are or considerable clinical importance, 
since it raises the question whether the low levels or 
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antibodies to myotoxin observed at and arter twenty-Four 
hours are adequate to neutralize myotoxin ~-induced 
myonecrosis. This is a particularly important question 
because it is known that degenerative errects due to 
myotoxin can continue ror a matter or days. In addition it 
is important to keep in mind that these values represent 
the disappearance or crude antiserum, however not in the 
presence or myotoxin ~- The errect or myotoxin ~ on the 
disappearance or the crude antiserum is addressed in a 
later study. 
CHAPTER V 
THE USE OF ELISA TO DETECT CHANGES IN BLOOD 
LEVELS OF CRUDE ANTISERUM IN THE 
PRESENCE OF MYOTOXIN A 
Introduction 
The enzyme-! jnked immunosorbent assay (ELISA) is a 
technique which is gaining popularity in the area of venom 
research. Recently Theakston (1983) has reviewed the 
advantages and possible applications of ELISA in clinical 
studies of snake venom poisoning. The ELISA has since been 
used successfully in field and clinical trials to detect 
blood-venom levels of snakebite victims. In Australia the 
ELISA has been developed for the rapid detection of venom 
in bite site swabings and blood samples (Coulter et al., 
1980), and in Thailand ELISA has been used to measure venom 
levels in the blood of snakebite victims (Ho et al., 
1986b). Using ELISA, Ho et al. (1986b) observed that the 
blood-venom (Calloselasma rhodostoma) · levels of snakebite 
victims can slowly increase following the initial dec! ine 
of blood-venom levels. Therefore patients who are released 
may later have a reappearance of symptoms associated with 
snake venom poisoning. 
Although the role and importance of ELISA in venom 
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detection is considerable, few investigators have used 
ELISA to monitor blood-antivenom levels. Theakston et al. 
(1981) have used ELISA to measure blood levels of anti-
bodies produced by previous snakebite victims, however 
blood levels of experimentally injected antfvenom have not 
been studied. 
In the United States rattlesnake venom poisoning often 
results in local tissue damage. Ownby et al. (1976) 
isolated a myotoxic component, myotoxin ~' from the Pairie 
rattlesnake (Crotalus viridis viridis) venom and produced 
an antiserum to the pure myotoxin ~(Ownby et al., 1979). 
The antimyotoxin ~serum is more effective in neutralizing 
local myonecrosis than the commerical ly produced Wyeth's 
polyvalent (Crotalidae) antivenin. However, the polyvalent 
antivenin is more effective· in neutralizing lethality 
(Ownby et al., 1983a). 
It would be of considerable interest and help to 
detect and monitor blood antfvenom levels in the presence 
and absence of the toxin. Decisions to administer more or 
less antivenom could be made in part on the basis of blood-
antivenom levels. Therefore, an experiment was designed 
that used ELISA to measure the disappearance of blood-
antivenom in the presence of known amounts myotoxin ~· 
Materials and Methods 
Myotoxin a 
Myotoxin ~ was purified by Ownby and Colberg 
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(unpublished results) and the myotoxin was tested ror its 
biological activity activity on skeletal muscle in mice as 
described in Chapter III. 
Crude Antiserum 
Serum was obtained From a rabbit immunized with pure 
myotoxin §as described in Chapter III. The crude 
antiserum was tested on a 1% agarose gel dirrusion plate 
against myotoxin § ror a single precipitin band. Previous-
ly this antiserum has been shown to neutralize the myotoxin 
activity or 0.75ug/g myotoxin §(Ownby et al., 1983a). 
Disappearance or Crude Antiserum 
Forty-rive remale mice weighing 25 ± 0.50g (CD-1, 
Charles Rivers) were divided into nine groups, rive mice 
per group. All intravenous injections (i.v.) were given 
via the tail vein and all intramuscular injections (i.m.) 
were given into the dorso-lateral aspect or the right hind 
thigh or the mice. Crude antiserum was always injected 
i.v. toxin or PSS was injected i.m. The volume or crude 
antiserum was 0.20ml and the volume or PSS or toxin was 
0.05ml. The nine groups were as rol lows: 1) crude 
antiserum 5 min beFore 1.5~g/g myotoxin §, 2) crude 
antiserum 5 min berore 0.75~g/g myotoxin ~' 3) crude 
antiserum 5 min beFore PSS, 4) crude· antiserum immediately 
arter 1.5~g/g myotoxin ~. 5) crude antiserum immediately 
arter 0.75~g/g myotoxin ~' 6) crude antiserum immediately 
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arter PSS, 7) crude antiserum 30 min arter 1.5~g/g myotoxin 
2• 8) crude antiserum 30 min arter 0.75~g/g myotoxin 2 and 
9) crude antiserum 30 min arter PSS. Blood samples 
(0.04ml) were taken rrom the tail vein using a capillary 
tube and immediately diluted in 0.960ml incubation burFer 
11. BSA. Blood samples were taken immediately (zero time) 
and, 0.5, 1, 3, 6, 24, 48, 72 and 96h aFter the antiserum 
injection. 
Antibody Detection ELISA 
All blood samples were assayed in duplicate using the 
antibody detection-ELISA as described in detail in Chapter 
IV. Pure myotoxin 2 (1~g/ml) was used to coat the micro-
titer plates and arFinity puriFied antimyotoxin was used 
For the standard curve. A standard curve and control 
samples were included with each microtiter plate. 
Results 
Figure 10 shows the blood disappearance or 
antimyotoxin 2 at 0.0, 0.5, 1, 3, 6, 24, 48, 72 and 96h 
from mice injected (i.v.) with antiserum thirty minutes 
after an injection of PSS (i.m.). The blood level of 
antimyotoxin 2 at zero time was 675 ng/ml, however there 
was a large amount or variation between animals. The 
variation between animals was considerably less at the 
later time periods. Antimyotoxin was still detectable at 
twenty-Four hours, however at 48, 72 and 96 hours 
antimyotoxin was non-detectable in the blood. 
Figure 10. The disappearance or antimyotoxin 2 when 
injected (i.v.) 30min arter PSS (i.m.). 
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Figures 11 and 12 show the blood disappearance of 
antimyotoxin at 0.0, 0.5, 1, 3, 6, 24, 48, 72 and 96 hours 
from mice injected (i.v.) with antiserum thirty minutes 
after an injection ( i. m.) of 0. 75 and 1. 5 ~~/~Lmyotox in §_, 
respectively. At zero time both groups had detectable 
levels of antimyotoxin §_,although the group receiving 0.75 
ug/g had a significantly (p<0.05) higher level of antibody 
at zero time than the 1.5 ~g/g treated group. However, 
both groups showed a rapid decline in the level of blood-
antimyotoxin. At 0.5h and for all later samplings the 
antibody was non-dectable. 
Figure 13 shows the blood disappearance of 
antimyotoxin at 0.0, 0.5, 1, 3, 6, 24, 48, 72 and 96 hours 
from mice injected (i.v.) with crude antiserum immediately 
followed by an (i .m.) injection of PSS. Blood antimyotoxin 
remained constant at zero time and thirty minutes followed 
by a gradual dec! ine at one and three hours. However, a 
fairly constant level of blood-antimyotoxin (268-236ng/ml) 
was maintained for all other sampling times. Antimyotoxin 
~ was detectable at each time period. 
Figures 14 and 15 show the blood disappearance of 
antimyotoxin at 0.0, 0.5, l, 3, 6, 24, 48, 72 and 96 hours 
from mice when crude serum was injected (i .v) immediately 
after an (i.m.) injection of 0.75 and 1.5 ~g/g myotoxin ~· 
respectively. Mice injected with 0.75 ~g/g myotoxin ~had 
427 ng/ml of antimyotoxin at zero time but rapidly declined 
to non-dectable levels for al 1 other time periods. Mice 
Figure 11. The disappearance of antimyotoxin .§.when 
injected (i.v.) 30min after 0.75~y/g 
myotoxin (i.m.). 
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Figure 13. The disappearance or antimyotoxin ~when 
injected (i.v.) immediately arter PSS 
(i.m.). 
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l.S~g/g myotoxin (i.m.). 
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injected with 1.5 ~g/g had 648 ng/ml blood-antimyotoxin at 
zero time. Antimyotoxin rapidly declined to a 
signiFicantly less (p<0.05) value or 75 ng/ml. Al 1 other 
sampling times had non-detectable levels or antimyotoxin 
~· 
Figure 16 shows the blood disappearance or antimyo-
toxin at 0.0, 0.5, 1, 3, 6, 24, 48, 72 and 96 hours From 
mice injected (i.v.) with crude antiserum rive minutes 
beFore an (i.m.) injection or PSS. Blood-antimyotoxin was 
detectable at each sampling period. Antimyotoxin was 729 
ng/ml at zero time and declined to 156 ng/ml at 96h. 
Figures 17 and 18 show the blood disappearance or 
antimyotoxin at 0.0, 0.5, 1, 3, 6, 24, 48, 72 and 96 hours 
For mice injected (i.v.) with crude antiserum rive minutes 
beFore an (i.m.) injection or 0.75 and 1.5 ~g/g or myotoxin 
~· respectively. Mice injected with 0.75 ~g/g had 799 
ng/ml or antimyotoxin at zero time rol lowed by a rapid 
decline to non-dectable levels at al 1 other time periods. 
Mice injected with 1.5 ~g/g had 1110 ng/ml antimyotoxin at 
zero time rol lowed by a rapid decline to non-detectable 
levels or blood antimyotoxin at al 1 other time periods. 
Discus~ ion 
The presence or myotoxin ~ quickly and signiFicantly 
(p<0.05) reduced the blood levels or antibody to myotoxin. 
Antibody levels were non-detectable at thirty and sixty 
minutes ir the toxin was present, whereas ir toxin is 
Figure 16. The disappearance or antimyotoxin §when 
injected (i.v.) Smin berore PSS (i.m.). 
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Figure 17. The disappearance of antimyotoxin §when 
injected (i.v.) 5min before 0.75~g/g 
myotoxin (i.m.). 
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absent antibody levels were detectable with each sampling. 
Injections or myotoxin at either (1.5 or 0.75~g/g) resulted 
in a sharp and rapid decrease or antibodies to myotoxin 
-· 
from the bloodstream. Animals receiving the antiserum 
thirty minutes after an injection or toxin 0.75 or 1.5~g/g 
had the lowest levels or antibody at zero time compared to 
the other toxin treated groups. This result is especially 
important since not only is the toxin stil 1 capable or 
binding to the antiserum, even though the antiserum is 
injected thirty minutes arter the toxin, but in fact more 
toxin is binding to the antiserum than at any other time as 
indicated by the lower levels or antibody at zero time. 
Blood levels of antibody to myotoxin were non-detectable at 
thirty miQutes ror all groups receiving 0.75~g/g toxin, 
thus the addition or more myotoxin did little to change the 
disappearance rate of antibody rrom the blood. 
This is the rirst report or the disappearance rate of 
antibodies to myotoxin in the presence or toxin. The-
values from the groups receiving toxin were obtained rrom 
thirty mice and without exception the same pattern or 
antibody disappearance was observed. This rapid decrease 
or antibodies to myotoxin was seen regardless of when the 
antiserum was injected, suggesting a sufficient amount of 
toxin was always available to bind the antiserum. 
Conversely, the animals injected with only antiserum 
demonstrated a gradual decline of antiserum from the 
bloodstream. A total of thirty mice were injected with 
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antiserum alone and although there was some variation 
between groups, without exception blood levels of 
antibodies to myotoxin were always detectable. These data 
show the striking effect myotoxin has on the disappearance 
rate of antibody and emphasises the need for physicians to 
monitor blood antivenom levels in snakebite patients. 
Snakebite victims may require more antivenom at some later 
time following the initial antivenom therapy since the 
presence of venom is quickly reducing blood antivenom 
concentrations. 
This particular study measured the disappearance of 
crude serum containing antibodies to myotoxin § rather than 
neutralization of myonecrosis. However, Ownby et al. 
(1984) have studied the in. vivo ability of this same lot of 
antiserum to neutralize local myonecrosis induced by 
myotoxin. Their results showed that antimyotoxin § serum 
neutralizes the myotoxicity of 0.75~g/g myotoxin §when 
injected five minutes before or immediately after the 
toxin, but not when injected fifteen minutes or more after 
the toxin. The rapid decrease of blood-antimyotoxin 
observed in our study when either 0.75 or l.S~g/g of toxin 
was injected may reflect the in vivo binding of toxin and 
antibody even thirty minutes after toxin injection. It is 
important to realize that after thirty minutes of exposure 
to toxin that local muscle damage has probably already 
occured since Ownby et al. (1984) detected local 
myonecrosis fifteen minutes after an injection of myotoxin. 
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The decrease of blood levels of antibody to myotoxin 
observed even when antiserum is given thirty minutes after 
toxin may be due to 1) an excess of toxin that is available 
to bind to the antiserum or 2) a release of tissue bound 
myotoxin once local myonecrosis has already occured. The 
results indicate that blood level of antibodies to myotoxin 
quickly decrease regardless of when antiserum is injected. 
Antiserum administered as late as thirty minutes after the 
toxin can sti 11 bind the antigen, but myotoxin ~-induced 
myonecrosis has probably already occured. 
Although Ho et al. (1986b) did not measure blood-
antivenom levels, they did observe an increase in blood-
venom levels after antivenom therapy was discontinued. The 
results obtained in our experiments with known amounts of 
myotoxin ~ show the rapid effect the toxin has on blood-
antimyotoxin levels and suggest ser.ial injections of 
antiserum may be needed to maintain high blood levels of 
antiserum. The results indicate that the disappearance of 
antimyotoxin in the absence oftoxin is considerably slower 
than when toxin is present. However, when the myotoxin has 
been present for thirty minutes prior to the antiserum 
Injection the antiserum blood levels decline rapidly. 
Considering the length of time that can elapse in rural 
regions of the world prior to treatment for snake venom 
poisoning this finding may be of practical significance. 
Thus, this study has shown that 1) the.antibody 
detection ELISA can detect nanogram amounts of antibodies 
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to myotoxin i..Q vivo 2) the decline of antimyotoxin §.is 
very rapid when myotoxin §. (0.75 or 1.5~g/g) is present and 
3) the rapid decline of antimyotoxin is observed even when 
the antiserum is injected thirty minutes after the toxin 
although muscle damage has probably already occured. 
CHAPTER VI 
THE USE OF ELISA TO SCREEN VENOMS 
FOR MYOTOXIN A 
Introduction 
Myotoxin ~is a small basic protein (4,400 dlatons, 
9.8 pi) that has been isolated From Crotalus viridis 
viridis venom (Ownby et al., 1976; Cameron and Tu, 1977) 
and is known to induce local myonecrosis (Ownby et al ., 
1976). In addition, Ownby et al. (1984b) have shown that 
the pure myotoxin induces a myonecrosis similar to that oF 
·the crude venom. An antiserum produced against the pure 
myotoxin has been reported to neutralize myonecrosis (Ownby 
et al ., 1983a). However, the commerical ly available 
Wyeth's polyvalent (Crotalidae) antivenin contains only 
trace amounts oF antibodies to myotoxin ~(Ownby et al., 
1983b). 
Basic toxins oF small molecular weight have also been 
isolated From venoms other than~- viridis viridis, i.e. ~ 
adamanteus, ~- durissus terriFicus and~. y. helleri, and 
have also been shown to induce myonecrosis. Crotamine a 
small basic protein is6lated From~-~- terriFicus var. 
' Crotaminicus venom (Goncalves, 1956) can aFFect the muscle 
eel 1 membranes in rats (Brazil et al ., 1979), while peptide 
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C isolated from~· y. hel leri also has similarities in 
amino acid composition to myotoxin e (Maeda et al., 1979). 
Mebs and Kornalik (1984) have isolated a basic toxin of 
approximately 5,800 daltons from the venom of ~· adamanteus 
having amino acid similarities to crotamine of~- g. 
terrificus, myotoxin §of~- y. viridis and peptide C from 
~- y. hel leri. 
It is of practical significance to understand the 
similarities and differences between venoms and 
particularly important to be aware of the presence or 
absence of known deleterious snake venom toxins. If 
myotoxin ~ is a widely distributed protein among different 
venoms then an efficacious polyvalent antiserum must 
contain antibodies to myotoxin. Therefore, a study was 
performed using ELISA that screened eighty-two venoms from 
six genera having a wide geographic distribution for the 
presence of a protein known to induce local myonecrosis, 
myotoxin e (Ownby et al ., 1976). Presence or absence of 
detectable levels of myotoxin was then compared with 
respect to the geographic orgin, genus and species of the 
snake. 
Recently, antibodies to myotoxin § have been purified 
using affinity chromatography (Chapter Ill), thus providing 
and excellent reagent for an ELISA antigen detection system 
which was used in the current study. 
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Materials and Methods 
Antigen Detection ELISA 
Microtiter plates (Flow Laboratories, Mclean, VA) were 
coated with two-hundred microliters of affinity purified 
antimyotoxin (1 ug/ml). The antibody was diluted with 
coating buffer, pH 9.6. The plates were incubated 
overnight at 4 C. The following day the plates were rinsed 
three times with washing buffer, allowing a five minute 
soaking period between each washing. Following the final 
rinsing two-hundred microliters of known amounts of antigen 
or sample were added to each wel 1 and incubated one hour at 
37 C. The m~otoxin 2 solutions for the standard curve were 
diluted with incubation buffer. The antigen solutions for 
the standard curve consisted of the following concentra-
tions: 100, 80, 60, 40, 20, 10, 5 and 1 ng/ml. Four wells 
coated with antimyotoxin received two-hundred microliters 
of incubation buffer alone and were assayed for non-
specific binding. After the one hour incubation plates 
were rinsed three times with washing buffer and following 
the final rinsing two-hundred microliters of 1 ~g/ml 
affinity purified antibody in incubation buffer were added 
to each sample well. Micro~iter plates were allowed to 
incubate one hour at 37 C and then rinsed three times with 
washing buffer. Following the final rinsing two-hundred 
microliters of goat anti-rabbit IgG (Sigma, St. Louis, MO) 
were added to each sample well. The goat anti-rabbit IgG 
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was diluted 1:2000 with incubation buFFer containing 1% 
BSA. Plates were again incubated at 37 C For one hour and 
then rinsed three times with washing buFFer. Following the 
last rinsing two-hundred microliters oF phosphatase 
substrate {p-nitrophenyl phosphate disodium, Sigma, St. 
Louis, MO) were added to each well. The substrate was 
diluted to 1 mg/ml with diethanolamine buFFer, pH 9.8. 
Substrate was allowed to incubate For thirty minutes at 
room temperature. The reaction was stopped with 0.050ml 3N 
NaOH and the absorbance oF each well was read with an EIA 
manual reader at a wavelength oF 405nm. The amount oF color 
Formed is proportional to the amount or antigen present. 
Screening Venoms 
For Myotoxin a 
Eighty-two snake venoms From the genera Crotalus, 
Agkistrodon, Bothrops, Bitis, Naja and Vipera were provided 
by James L. Glenn, Veterans's Administration Medical 
Center, Salt Lake City, Utah. Venoms samples were From 
various geographic orgins including Arizona, Cal irornia, 
Florida, Georgia, Kansas, Louisana, North Carolina, New 
Mexico, Texas, Utah, Virginia, Wyoming, Brazil, India, 
Mexico Thailand and Venezuela. Al 1 venom samples were 
received Jyphol ized and later diluted with PBS, pH 7.4 to l 
mg/ml. AlI venom samples were assayed using the ELISA 
antigen detection plates For the presence or myotoxin 2· 
IF the absorbance reading obtained For any venom sample was 
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over 2.0 the sample was diluted 1:1000 and assayed again. 
Results 
Antigen Detection ELISA 
Figure 19 shows a flow chart of the steps involved in 
the myotoxin ~detection assay. Non-specific binding was 
very low with absorbance readings between 0.110 and 0.122. 
Table VIII shows the absorbance readings for three standard 
curves using known amounts of purified myotoxin. The 
correlation coefficients are 0.97, 0.96 and 0.99 for the 
three antigen standard curves. The small differences 
between duplicate samples are reflected in the very low 
standard errors. Differences in absorbance readings for 
the same concentration of antigen is due at least in part 
to differences between microtiter plates. 
Screening Venoms 
Table IX lists the eighty-two venoms, their geograph-
ical orgins and the results of the myotoxin ~detection 
assay. Venoms from the genera Agkistrodon, Bothrops, 
Bitis, Na.ia and Vipera did not have detectable levels of 
myotoxin ~at a concentration of lmg/ml regardless of their 
geographic orgin. Myotoxin § is present most frequently in 
the crotaline venoms of Montana, Colorado and Wyoming. 
Crotalus viridis viridis, ~- durissus and ~- molossus 
commonly have detectable levels of myotoxin ~. however~-
Figure 19. A flow chart illustrating the steps 
involved in the myotoxin ~detection 
plate. 
ELISA FOR MYOTOXIN a DETECTION 
1. ANTI-MYOTOXIN a \::::J ADSORBED TO PLATE 
WASH 
.. 
2. SOLUTION CONTAINING MYOTOXIN a 
0 ADDED 
WASH 
... 
3. SOLUTION (!ONT AINING ANTHAYOTOXIN a 
'\::::J ADDED 
WASH 
.. 
4. ALKALINE PHOSPHATASE LABELLED 
ANTIBODY TO RABBIT ~w:O 
WASH 
.... 
5. ENZYME SUBSTRATE 0 ADDED 
INCUBATE 
• 
8. READ ABSORBANCE OF REACTION 
PRODUCT 0 AT _.OSnM 
E 
l·~·~ 
0 0 
0 E 0 
l·1fi·l 
9 
E lo-·-c&-·-ol 
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TABLE VIII 
DETECTION OF MYOTOXIN A USING ELISA 
Ag (ng/ml)* Plate 1 Plate 2 Plate 3 
Absorbance 405 (nm) 
100 1.39 + .01 1.00 + .22 1. 64 + . 23 
80 1 • 29 + . 23 1 • 28 + • 1 1 1 • 42 + . 0 1 
60 0.75 + .01 0.84 + .14 1 . 00 + . 02 
40 0.87 + .13 0.58 + .01 0.71 + .05 
20 0.25 + .02 0.19 + .02 0.24 + .03 
10 0. 09 + • 01 0. 08 + • 01 0.12 + .003 
.5 0.04 + .002 0.04 + .003 0.04 + .004 
0.01 + .000 0.01 + .01 0.00 
IB 0.11 + .001 0.12 + .003 0.12 + .01 
* Ag = myotoxin §. The antigen standard curve was 
assayed on three diFFerent microtiter plates. Al 1 
sample~ were assayed in duplicate. Expressed as mean + 
standard error. 
** LB = incubation buf"f"er· 1% BSA. Sample wells were 
coated with aFFinity puriFied antibody and IB was 
assayed for non-specific binding. The background 
values have ben subtracted 'from each absorbance. 
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TABLE IX 
SCREENING VENOMS FOR MYOTOXIN A WITH ELISA 
Venom 1 mg/ml 1 J-19/ml 1 ng/ml 
A· Q· b i l i neat us ** 
unknown orgin 
A· £· mokesona ** 
Miami Serpentarium 
A· £· rhodostoma ** 
Thailand 
A· e. leucastoma ** 
Louisiana 
Bit is arietans ** 
unknown orgin 
Both roes a seer 
unknown orgin 
Both roes atrox 
comerical venom 
Braz i l 
Crotalus adamanteus 
Florida 
~- adamanteus * 
Florida 
~- atrox * 
Texas 
~- Q. basil iscus ** + + 
unknown orgin 
f. cata l i nens is * + 
Cata l ina Island 
~- cerastes * 
Miami Serpentarium 
c. ~- cerastes_ ** + 
Utah 
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TABLE IX (Continued) 
Venom 1 mg/ml 1 J-.19/ml l ng/ml 
£. g. culminatus ** + 
Houston Zoo 
£. g. durissus ** + + 
unknown 
£. g. terri ficus ** + 
Venezuela 
£. g. totonacus ** + + 
unknown 
£. g. tzabcan ** + 
Yucatan 
£. exsul * + 
unknown orgin 
£. exsul * + + + 
unknown orgin 
£. ~- en yo ** 
Baja Sur 
£. b· atricaudatus ** 
Georgia 
£. b· atricaudatus ** 
North Florida 
£. b· atricaudatus ** + 
unknown orgin 
£. b· horridus ** 
Kansas 
£. b· horridus ** + + 
North Caro 1 ina 
Table IX (Continued) 
Venom 
~. l· klauberi ** 
Durango 
~- l· klauberi ** 
Mexico 
~- l· klauberi ** 
Mexico 
1 mg/ml 
~. l· klauberi ** + 
New Mexico 
~. ffi· mitchel 1 i ** 
Baja Sur 
~- ffi· mitchel·li ** 
Mulege, Baja 
~- ffi· pyrrhus ** 
Arizona 
~- ffi· pyrrhus ** + 
Bajia de los Angeles 
~- ffi· pyrrhus ** 
Bajia de los Angeles 
~. ffi· pyrrhus ** 
Mexico 
~ ffi· pyrrhus ** 
Smith Isle 
1 1-Jg/m 1 
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1 ng/ml 
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TABLE IX (Continued) 
Venom 1 mg/ml 1 fJ9/ml 1 ng/ml 
~- ffi· e~rrhus ** 
Utah 
~- !!!· e~rrhus ** 
Utah 
~- ffi· e~rrhus ** 
Utah 
~- !I!· e~rrhus ** 
Utah 
~- ffi· e~rrhus ** 
Utah 
~- ffi· e~rrhus ** 
Utah 
~- ffi· e~rrhus ** 
Utah 
~- !I!· e~rrhus ** 
Utah 
~- ffi· e~rrhus ** 
Utah 
~- !!!· steehensi ** 
orgin unknown 
~- ffi· molossus *** + + 
Texas 
~- !I!· nigrescens *** + + 
Durango, Mexico 
~. ruber ruber + + 
San Ignacio 
~. ruber ruber 
San Marcos Is 1 . 
~- vegrandis * 
Venezuela 
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TABLE IX (Continued) 
Venom 1 mg/m1 1 }-Jg/m 1 1 ng/m1 
~- y. ab:t:SUSS ** + 
Arizona 
c. v. ab:t:SSUS ** 
Sonoran Desert Museum 
~. v. cerberus ** + 
unknown orgin 
~- y. concolor ** + 
Wyoming 
~- y. he 1 1 er i ** + 
orgin unknown 
~· v. lutosus ** 
Arizona 
~· y. lutosus ** + 
Neveda 
~- y. lutosus ** 
Utah 
~- y. nuntius ** 
Utah 
~- y. organ us ** + + + Washington 
~- y. viridis ** + 
Colorado 
~- y. viridis ** + 
Colorado 
~- y_. viridis ** + + 
Colorado 
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TABLE IX (Continued) 
Venom l mg/ml l fJg/ml 1 ngjml 
~- y_. viridis ** 
Colorado 
~- y_. viridis ** + + 
Montana 
~- y_. viridis ** + 
Montana 
~- y_. viridis ** 
New Mexico 
~- v. viridis ** 
New Mexico 
~. y_. viridis ** + 
New Mexico 
~- y_. viridfs ** 
New Mexico 
~- y_. viridis ** + 
South Dakota 
~- y_. Viridis ** 
Texas 
~- y_. viridis ** 
Texas 
~- y. viridis ** + 
Wyoming 
~- y_. viridis ** + 
Wyoming 
~- y. viridis ** + 
Wyoming 
TABLE IX (Continued) 
Venom 
~- y. viridis ** 
Wyoming 
~- y. viridis ** 
Wyoming 
~- n. kaouthia ** 
unknown orgin 
Vipera L· russell i ** 
India 
1 mg/ml 1 }JQ/m 1 
+ 
+ 
1 ng/ml 
* Venom samples were diluted with PBS, pH 7.4 to 1 
mg/ml then assayed with ELISA. If a positive result 
was obtained the venom sample was diluted 1:1000 and 
a~sayed again. Beneath each venom is given the geo-
graphical orgin. ~- = Agkistrodon, ~. = Crotalus, 
· fi. == NaJa. 
** Species and subspecies are as follows: ~. 
bil ineatus Q.; ~· contortrix m.; ~. cal lesolasma r.; 
6· piscivorus l·; ~· basil iscus Q.; ~· cerastes ~.;g. 
= durissus; ~· = enyo; h· = horridus; l· = lepidus; ffi· 
= mitchel lii; y. = viridis; n = naja; r =russell i. 
*** ffi· = molossus 
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mitchelli has almost consistently non-detectable levels of 
the toxin. 
Discussion 
The use of the antigen detection ELISA to screen 
venoms for the presence of myotoxin § has helped to 
identify genera and species with particularly high levels 
of the toxin. A total of eighty-two venoms from six genera 
(Agkistrodon, Bitis, Bothrops, Crotalus, Naja and Vipera) 
were assayed for the presence of detectable levels of 
myotoxin g. Only venom from the genus Crotalus had 
detectable levels of myotoxin g. Seventy-four crotaline 
venoms were assayed and of these thirty-four (45%) had 
detectable levels of myotoxin §. Myotoxin appeared 
predominately in the species ~. viridis, ~- molossus and 
~. durissus with a greater distribution of toxin appearing 
in the north and southwest regions of the United States, as 
well as Mexico and South America. Ownby et al. (1986b) 
have shown that the commerical ly available Wyeth's 
polyvalent (Crotalidae) antivenin has an extremely low 
titer of antibodies to myotoxin g when tested with ELISA. 
Consider1ng the number of of crotaline venoms which have 
detectable amounts of myotoxin §an efficious antivenom 
should contain a neutralizing antibody to myotoxin §. 
Our ELISA results indicate that the presence of 
myotoxin § in venom samples.varied with genera and 
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geographic orgin. Glenn and Straight (1978) have also 
observed variation in toxicity with geographic orgin for 
the Mojave rattlesnake (Crotalus scutulatus scutulatus) 
Venom from specimens collected in southern California and 
southwest Arizona was different in lethality and reactivity 
with the commerical antivenin from venom or specimens 
collected in central and northwest Arizona. Venom samples 
from southern California and southwest Arizona were poorly 
neutralized by the antivenin in comparison to venom samples 
from northwest and north central Arizona. The geographic 
variation seen within the subspecies could possibly help 
explain some or the varying clinical aspects or Mojave 
rattlesnake bites (Glenn and Straight, 1978). 
Interestingly, Glenn et al. (1983) have observed a 
higher proteolytic activity in venoms or ~· ~· scutulatus 
that had little to none or the lethal toxin, Mojave toxin. 
These data are similar to results obtained with~- atrox 
venom (Minton and Weinstein, 1986). Crotalus atrox venom 
differs with geographic orgin with an inverse relationship 
between proteolytic activity and lethality being observed. 
A geographic distribution has also been noted for 
crotamine, a basic protein known to induce myonecrosis, 
from Crotalus durissus terriricus venom. Venom from ~. g. 
terriricus inhabitating northeastern Brazil are missing the 
basic polypeptide, whereas specimens rrom southern Brazi 1, 
Argentina and Venzezuela possess this particular venom 
component (Glenn and Straight,. 1982). Variation between 
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venom samples however, does not require large geographic 
distances, on the contrary variation between venom samples 
from individual snakes of same litter can occur. Mebs and 
Kornalik (1984) found that venom samples from four 
specimens of~. adamanteus from the same litter differed in 
the presence or absence of a small basic toxin. Venom from 
two of the snakes possessed the toxin and the venom from 
the two other snakes were essentially free of the toxin. 
Individual or geographical variation within a 
subspecies however, are often times not observed since many 
of the lethal toxicities reported are derived from pooled 
venoms, especially if the venoms are commerically supplied 
(Glenn and Straight, 1982). The study of variations in 
venom composition and venom toxicity with geographic orgin 
is important in order to provide better treatment for 
snakebite poisoning and to better understand taxonomic 
differences. The ELISA is possibly the most economical, 
rapid and sensitive test for screening venoms for specific 
toxins and detecting the individual and geographic 
variations of snake venoms. 
CHAPTER VII 
SUMMARY AND CONCLUSIONS 
Antibody produced against myotoxin § from Crotalus 
viridis viridis venom was purified using affinity 
chromatography. Myotoxin §was conjugated to Affi-Gel 10 
and samples of crude antiserum were applied to the column, 
followed by washings with PBS, DW and acetic acid. 
Antimyotoxin § was eluted with each of the effluents. The 
antibody was measured with the antibody detection enzyme-
linked immunosorbent assay (ELISA) and later tested for its 
~bility to neutralize myotoxin-induced myonecrosis. The 
affinity purified antimyotoxin §was used to develop a 
sensitive antigen and antibody ELISA. Antibody eluted with 
DW had the largest amount of protein as determined by Azso 
and was used routinely to coat our ELISA antigen plates or 
for a standard curve with the EL1SA antibody detection 
system. Antimyotoxin § eluted with DW, acetic acid and PBS 
each reduced the myotoxin-induced myonecrosis when mixed 
and incubated together prior to intramuscular injections in 
mice, however there was a great deal of animal variation 
and the decrease was·not significant (p<0.05). 
The antibody detection ELISA was used to measure the 
disappearance of three concentrations of crude antiserum 
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from the blood of mice during a four week period. 
Regardless of the amount of antibody injected a slow 
decrease in the amount of antibody occurred during the 
first ninety-six hours resulting in non-detectable levels 
at two and four weeks. The mice injected with the greatest 
concentration of antibody had initially higher blood-
antibody levels however, antibody was non-detectable at 
four weeks. The antibody detection ELISA is capable of 
detecting and monitoring changes in blood-antibody levels 
at nanogram concentrations. 
Animal variation is a significant problem when using 
the ELISA systems to measure disappearance of antibodies 
from the blood and demonstrates the need to use either very 
large numbers of smal.l laboratory animals or larger animals 
whereby indwelling cathers could be used. HowevPr, either 
because of cost limitations or quantity of rurified 
antiserum and toxin such experiments are not always 
feasible. These limitations do not preclude the use of 
ELISA to study the disappearance of antibody from the blood 
in laboratory animals. The ELISA is capable of monitoring 
and detecting decreases in antibodies to myotoxin from the 
blood and distinct patterns in the rate of antibody 
disappearance in the presence or absence of toxin can be 
observed using the ELISA system with mice. It is equally 
important to realize the ELISA systems are sensitive and 
reliable assays as indicated by the smal 1 variation 
assoicated with the standard curves. Also, non-specific 
binding never posed a problem and remained always low ror 
all experiments. 
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The disappearance or antibodies to myotoxin rrom the 
blood in the presence or known amounts or myotoxin 2 (0.75 
and 1.5~g/g) or physiological saline (PSS) has been 
compared. A marked dirrerence was observed in the 
disappe~rance rate or the antiserum in the presence or 
absence or toxin. Whenever myotoxin § was injected, 
regardless or amount or toxin or time or administration, a 
rapid decline in blood levels or antibodies to myotoxin 
also occurred. Conversely, a gradual decline or blood-
antiserum was observed over a 96h period when PSS was 
injected instead or toxin. The presence or the toxin 
causes a rapid clearance or the antiserum even when the 
toxin is injected thirty minutes prior to the antiserum. 
Both concentrations or toxin selected (0.75 and 1.5~gjg) 
caused a rapid decline or speciric antibodies to myotoxin 
rrom the blood. Antibody declined in a similar manner when 
the antiserum was injected 1) rive minutes berore the 
toxin, 2) immediately arter the toxin or 3) thirty minutes 
arter the toxin. The latter rinding has considerable 
clinical signiFicance since it indicates either that there 
is stil 1 enough toxin available to bind the antibody even 
arter thirty minutes or the toxin might induce local 
myonecrosis and then bind the antibody. Multiple 
injections or antiserum may be necessary to maintain high 
blood levels or antimyotoxin. 
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The ELISA antigen detection system has been used to 
screen eighty-two venoms or six genera For the presence or 
myotoxin ~· Venoms From the genera Agkistrodon, Bothrops, 
Bitis, Naja and Vipera did not have detectable levels or 
myotoxin ~· Numerous crotaline venoms (451.) did have 
myotoxin ~ present including Crotalus viridis, ~· durissus 
and~· molossus. Crotaline venoms or the north, 
northwest and southwest oFten times were positive For 
myotoxin ~ compared to the crotaline venoms or the 
southeast which Frequently had non-detectable levels or 
myotoxin ~· The antigen ELISA detection system is a rapid, 
reliable and relatively inexpensive means to screen venoms 
or various geographic orgins For the presence or speciFic 
toxins. 
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